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Using PCR with human papillomavirus E6 gene primers, we amplified an 
expressed sequence tag from the MOLT-4 T-lymphoblastic leukemia cell line. 
Via RACE and cycle sequencing, we characterized overlapping cDNAs of 
2786 bp and 2054 bp of the corresponding novel human intronless gene 
designated MOST-1 (for MOLT-4 Sequence Tag-1) from MOLT-4 and fetal 
lung cDNA libraries, respectively. Both cDNAs contained a potential ORF of 
297bp incorporating a methionine codon with an ideal Kozak consensus 
sequence for translation initiation, and encoding a putative hydrophilic 
polypeptide of 99 amino acids. Computational analysis of cDNA showed 
presence of 3 AUUUA mRNA destabilizing signals at its 3’ untranslated region 
(UTR), suggesting MOST-1 mRNA to be unstable. Additional computational 
analysis of putative ORF predicted MOST-1 protein to be unstable and non-
globular with a secondary structure mainly of extended sheets. 
Although RT-PCR demonstrated MOST-1 expression in all 19 cancer and 2 
normal cell lines tested, only differential expression was observed in 9 out of 
16 normal tissues tested (heart, kidney, liver, pancreas, small intestine, ovary, 
testis, prostate and thymus).  
The MOST-1 gene was mapped by FISH to chromosome 8q24.2, a region 
amplified in many breast cancers and prostate cancers, and is also the candidate 
site of potential oncogene(s) other than c-myc located at 8q24.1. Analysis of 
paired biopsies of invasive ductal breast cancer and adjacent normal tissue by 
semi-quantitative and real-time RT-PCR revealed average tumor: normal ratios 
 xiv
of MOST-1 expression that were two-fold greater in grade 3 cancers compared 
with grade 1 and 2 cancers. Quantitative real-time PCR of archival prostatic 
biopsies displayed MOST-1 DNA levels that were 9.9, 7.5, 4.2 and 1.4 times 
higher respectively in high, intermediate, low grade carcinomas and benign 
hyperplasias than in normal samples.  
In an attempt to elucidate MOST-1 function, a polyclonal antibody was 
raised. Characterization of the polyclonal antibody showed that it only 
recognizes the aggregated form of MOST-1 protein. Confocal 
immunofluorescence microscopy showed punctuate pattern of the MOST-1 
aggregated protein in human cell lines namely hTERT-HME1 normal human 
mammary epithelial, MCF7 breast adenocarcinoma, PrEC normal human 
prostate epithelial and DU145 prostate carcinoma. Aggregation of 
overexpressed or misfolded proteins has been implicated in neurodegenerative 
disorder and many cancer types. Knock down of MOST-1 expression levels via 
RNA interference suggested that MOST-1 is needed for cancer cells 
proliferation. Yeast two-hybrid screening revealed interactions of MOST-1 
with 8 partner proteins namely creatine kinase, ferritin, peripheral 
benzodiazepine receptor, immunoglobulin C (mu) and C (delta) heavy chain 
genes, SNC73 protein, Gardner feline sarcoma v-FGR and telethonin. Most of 
the interactors are reported to be amplified or deregulated in tumors with a 
majority involved in cell cycle or energy metabolism. Co-immunoprecipitation 
assays validated the interaction of MOST-1 with 3 of the proteins, 
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immunoglobulin C (mu) and C (delta) heavy chain, ferritin and peripheral 
benzodiazepine receptor.  
Taken together, MOST-1 appears to be involved in cancer progression and 
its interaction with interactors involved in energy metabolism and cell cycle 
suggest a mitogenic function. 
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CHAPTER 1. INTRODUCTION 
Following the publication of a working draft of the human genome 
sequence (Venter et al, 2001), the Human Genome Project (HGP) functions as 
a scaffold for the identification of the estimated 35,000 genes residing within 
three billion base pairs of DNA, the characterization of their regulatory 
elements, transcriptional units and translated products (Wright et al, 2001). 
Deregulation of gene expression result in cancer. Carcinogenesis has been 
shown to be a multifactor process in which genetic aberrations involving large 
amplicon containing multiple genes are often implicated (Ethier S, 2003). One 
of the ways to isolate these numerous expressed genes amidst large tracts of 
non-coding genomic DNA is the use of expressed sequence tags (ESTs) which 
represents an efficient and economical “short-cut” route for gene identification. 
The idea of exploiting ESTs has been established as a practical approach for 
the discovery of novel human genes (Adams et al, 1991; Sim and Chow, 1999). 
The search for ESTs and their corresponding genes implicated in the causation 
of human cancers is intensifying in the quest for better diagnostic markers and 
therapeutic agents (Strausberg, 2001; Onyango, 2002).  
Since viral-induced cancers account for approximately 15% of human 
cancers, searching for genes deregulated by these viruses allows a directed 
search for potential genes involved in carcinogenesis. In particular, certain 
viruses have been shown to contribute significantly to the development of 
specific cancers such as the association of human papillomavirus (HPV) and 
carcinomas. Studies have shown that progression of HPV infected cells to 
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malignant phenotype requires further modifications of host gene expression; 
however molecular pathways underlying this phenomenon are still poorly 
understood despite epidemiological evidence (Kaufmann et al, 2002; Fiedler et 
al, 2004). In 1991, Couturier et al reported integration of HPV in cellular 
genomes near myc gene in genital cancers. This integration was found in most 
invasive genital carcinomas as compared to intraepithelial neoplasia where 
HPV DNA is detected most commonly as episomal molecules. This finding 
suggests a mechanism which may result in alteration of gene structure or 
overexpression of proto-oncogene. Subsequent work by Thorland et al in 2000 
showed integration into genome to be non-random with HPV 16 integration to 
frequently occur at common fragile sites suggesting presence of chromosome 
‘Hot Spots’ for viral integration. This also suggest that genes at or near the sites 
of integration may play an important role in tumor development as HPV 
integration could directly influence gene expression by changing the normal 
human DNA composition. Since HPV E6 early gene/oncoprotein of high-risk 
genital HPV types possess transforming abilities and are crucial in genital 
carcinogenesis (Chow et al, 2000; Stoler, 2000; Mantovani and Banks, 2001), 
this study was initiated in the view of isolating gene(s) near sites of HPV E6 
integration using E6 consensus primers. Isolation and characterization of these 
genes would allow better elucidation of the underlying processes of 
carcinogenesis and subsequent therapeutics. MOLT-4 T-lymphoblastic 
leukemia cell line, a cancer cell line established directly from leukemia patient 
with relapse, with no viral integration reported (www.atcc.org), was chosen for 
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mRNA extraction so as to reduce background amplification of E6. RT-PCR of 
MOLT-4 RNA using primers targeting the E6 genes of HPV types 11 and 18 
generated a novel EST of 350bp whose sequence revealed no significant 
homology to any known gene in the GenBank database and whose homology to 
HPV E6 primers as depicted below.  
 
HPV 18c  
5’ GGTTTCTGGCACCGCAGGCA 3’ 
                             5’ CCGCAGGCAGCCCACAGA……GAGACCAGCCTGGACAACATG 3’ 
       3’CTGGACAACATGCATGGAAG 5’ 
           HPV 11q  
         Novel EST 
 
 
Arising from this novel EST which bears no homology to E6 except for 
the region indicated above, a study of isolation and characterization of a novel 
human gene was initiated. The objectives of this study were as follow: 
1. To isolated full length cDNA; 
2. To analyze the genomic structure of MOST-1; 
3. To map its chromosome location; 
4. To characterize its expression profiles in human tissues, cell lines and 
clinical biopsies; and 
5. To produce polyclonal antibody for protein characterization. 
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2.1 Human genome project – scaffold for functional genomics 
Begun in 1990, the U.S. HGP was a 13-year effort to sequence the complete 
human genome. Along with it were project goals such as identification of all 
genes in human DNA, storing the information in databases, improving data 
analysis tools, transfer of technology to private sectors and to address the 
ethical, legal and social issues that may arise. The completion of sequencing 
has open up a new field of functional genomics into human health applications 
where genetics plays an important role in the diagnosis, monitoring and 
treatment of diseases. Medical genomics is at best at its infant stage as many 
genes are still under study as to how they contribute to the disease. The future 
challenge in genomics would be the elucidation of the function of each human 
gene. The goal after which would be to use the genetic information to develop 
new ways for prevention, treatment and cure. The next 20 years plan include 
the identification of more effective pharmaceuticals in which single base-pair 
variations in each individual can be used to 
• accurately predict responses to drug, and environmental substances;  
• anticipate disease susceptibility and aid in prevention;  
• aid in organ cloning; and 
• solve identity issues.  
Of course the major downside of all these would be the ethics issue of 
social bias and human rights. The next immediate stages now involve the 
functional genomics technology whereby 
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• sets of full-length cDNA clones and sequences that represent human genes 
and model organisms will be generated,  
• functional studies on nonprotein-coding sequences and its purpose in gene 
regulation;  
• analysis of gene expression,  
• genome-wide mutagenesis methodology development and 
• large-scale protein analysis;  
And the comparative genomics; which will encompass the complete 
sequencing of model organisms and appropriate genomic studies (adapted from 
www.onrl.gov). 
With the sequence, the next challenge would be the identification of the 
various genes, validation of their structure and characterization of their 
functions. Even after the identification, the next would be to understand how 
the molecular components of the cells are controlled, interact and function as a 
system. As the era of molecular biology transcends from genomics to 
proteomics, progress in methodology in protein characterization reaches a new 
height with post translational modification becoming the centre stage of 
molecular biology. Post translation modification has important implications for 
protein conformation diseases arising from loss of their catalytic activity, 
structure and stability (Ishimaru et al, 2003). These disease have protein 
aggregates as hallmarks and the process of aggregation have been shown to be 
peptide (Milewski et al, 2002) and size specific (Diamant et al, 2000) 
suggesting that delicate balance is needed for normal cell function.  
Literature Survey 
 7
The discovery and ability to manipulate RNA interference (RNAi) in 
mammalian cell lines, a process where the introduction of double stranded 
RNA into a cell inhibits gene expression in a sequence-dependent way for gene 
silencing effect allow rapid functional studies to be carried out. This in turn 
accelerate the speed of discovering protein function to the cell in general as 
well as identification, characterization and development for new molecular 
targets for cancer in replacement for limited effective conventional treatment 
presently available (Jansen B. et al, 2002). The development of these methods 
allows not only individual protein function characterization but also showed an 
overview of the protein interactors and cellular function. The rampant use of 
yeast-two hybrid (Y2H) interaction screening allows novel protein-protein 
interaction to be characterized as well as providing an insight to novel protein 
function based on the characteristic of the interactors. These tools are timely as 
cancer research repeatedly and consistently shows that large amplicon that 
contain multiple genes which together causes a deregulation in cell cycle 
(Ethier S, 2003). 
 
2.2 Genome research  
Genome research has taken off in leaps over the last decade with many 
techniques available for genome wide screening of gene copy number, 
expression and structure. There are basically 2 groups of techniques, the 
molecular cytogenetic group such as comparative genome hybridization (CGH) 
and FISH, and the molecular genetic techniques such as differential display and 
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microarray. Of these, CGH has become one of the popular genome scanning 
techniques for cancer research as it allows easy screening for DNA sequence 
copy number changes (Forozan et al, 1997). 
CGH is used to detect amplified or deleted chromosome regions in tumors 
by mapping their locations on normal metaphase chromosomes and has been 
used to screen for deletions and amplifications in several types of human 
neoplastic diseases (Angelis et al, 1999). 
Figure 1 below shows the principle of CGH. In brief, CGH is a modified in 
situ hybridization which uses differentially labeled test and reference DNA for 
co-hybridization on normal metaphase chromosomes. Quantitation of test to 
reference DNA using a digital imager allows gains or losses of test DNA to be 
seen. Subsequent confirmation of chromosomal location was then done with 
FISH (Forozan et al, 1997).  
 







TEST DNA  
(E.g. Tumor 
REFERENCE DNA  
(E.g. Normal tissue) 
Labeled Green Labeled Red 
Hybridize to normal metaphase spreads 
Imaging of color ratio 
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2.2.1. Comparative Genome Hybridization 
An overview of CGH studies of selected genital and urological tumors  
showed chromosome 8q to be most commonly gained in breast, ovarian, 
prostate, bladder and testicular tumors (Forozan et al, 1997) suggesting that 
there may be genes which are involved in common pathway for carcinogenesis 
irregardless of the tissue origin. CGH is also useful in the analysis of the 
biological basis of tumor progression process in which two cancer specimens 
from the same patient at different stages of progression can be analyzed. For 
example in one study, it appeared that CGH showed gain of 1q and 8q in breast 
cancer, and upon analysis, it was found that 1q appeared early on during tumor 
progression while 8q was suggested to be associated with subsequent tumor 
progression (Forozan et al, 1997). 
Chromosome 8 has been shown to contain genomic regions which are 
commonly amplified in a number of cancers as mentioned above. One of the 
most famous gene, and is also the candidate oncogene, found in this 
chromosome is c-myc at 8q24 (Garnis et al, 2004). There are also novel regions 
and genes which are implicated that are distinct from c-myc since c-myc 
amplification is not always found to be amplified in all cancers in vivo 
(Nupponen et al, 1998). In a recent study, RAD21 and K1AA0196 at 8q24 are 
found to be amplified and overexpressed in prostate cancer in addition to the 
common amplification of 8q23-24 in prostate cancer (Porkka et al, 2004). 
Other note-worthy studies showing 8q gain are the following studies such as 
CGH of tumor samples from young women ≤ 35 years of age with sporadic 
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breast cancer revealed genomic gains of 8q in 61.4% of the cases (Weber-
Mangal et al, 2003), DNA gains at 8q23.2 serve as a potential early marker in 
head and neck carcinomas (Da Silva Veiga et al, 2003) and  8q24.12-8q24.13 
segment being identified as a common region of over-representation in 10 
chronic myeloid leukemia-derived cell lines suggesting that this region could 
harbor gene (s) driving disease progression (Shigeeda et al, 2003). 
 
2.2.2. Alu repeats  and genetic aberrations  
With the complete sequence of the human genome, genetic research into 
database mining for repeat sequences has also intensified. It has been found 
that more than a third of the human genome consists of repetitive sequences. 
Almost all of these have arisen by retroposition of an RNA intermediate 
followed by insertion of the resulting cDNA into the genome. Of these, Alu 
elements are the most abundant class of interspersed repeats (Smit, 1999). Alu 
repeats comprise 5 to 10% of the human genome and are shown to hybridize 
preferentially to reverse bands (R-bands) of metaphase chromosomes 
(Holmquist, 1992). Cytogenetic studies of tumor cells have shown that 
recurring chromosomal abnormalities such as translocations, deletions and 
inversions are present in many tumors. Many of these rearrangements 
mechanisms proposed are sequence dependent. As shown in figure 2, there is a 
correlation between chromosomal abnormalities in cancer and presence of Alu 
repeats. Alu repeats has been shown to increase the recombination frequency 
between vector DNA and host genome loci (Kato et al, 1986, Wallenburg et al 
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1987, Kang et al, 1999) suggesting a role as a recombinant “Hot spot” for the 
Alu element. In addition to this finding, it has been shown that several genetic 
diseases have both a DNA instability phenotype and a high frequency of 
carcinogenesis. Several mechanisms leading to genetic instability have been 
suggested. Examples are mutations in mitotic checkpoint genes and loss of 
telomere capping function (DePinho and Polyak, 2004). This seems to suggest 
a correlation between recombination frequency, genetic instability and cancer 
predisposition (Bishop and Schiestl, 2000 and Hoeijmakers, 2001). 
 
Figure 2: Position of cancer breakpoints of recurrent chromosome 
aberrations mapped to Alu repeats within R-bands. 
 
Adapted from Kolomietz et al, 2002. 
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2.3 Cancer research 
 90% of all human malignancies are carcinomas (derived from epithelial  
cells), many of which are heterogeneous in their biological and clinical 
behavior thus warranting a greater understanding of their development and 
progress for better diagnosis and therapy (Alaiya et al, 2000). Correlative 
studies of genes and clinical outcome allows identification of biomarkers while 
understanding the mechanism of genetic basis of cancer progression would 
allow development of new therapies. One example of mechanistic approach in 
therapy development is the use of small molecule tyrosine kinase inhibitors as 
anti-tumor and anti-angiogenic agents  upon  understanding the role of tyrosine 
kinases in tumor progression (Morin 2000). 
 
2.3.1. Carcinogenesis – changes in the cell 
Cancer cells undergo a multistep process which lead to genetic changes 
that favors deregulated cell cycle, decreased apoptosis, increased invasion and 
metastasize properties. The initial transformation requires the cell to 
immortalize. Malignant transformation is generally associated with telomere 
maintenance which results in cell immortality. Normally, telomeres shorted 
every cell generation and once they reach a critical length, the cells die. 
Telomerase is the enzyme responsible for the maintenance of telomere length. 
Regulation of telomerase activity in turn, is via regulation of transcriptional 
control of telomerase catalytic subunit gene, human telomerase reverse 
transcriptase, hTERT. Termination of the life span through a pathway leading 
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to cellular senescence has been triggered by activation of p53 and/or pRb in 
response to critically shortened telomere DNA. To propagate indefinitely, the 
cell has to overcome this senescence checkpoint and activates telomerase. This 
is known as the telomere-induced crisis. This phenomenon has been shown to 
implicate in breast tumor progression (DePinho and Polyak, 2004) and oral 
keratinocytes immortalization (Kang and Park, 2001). Figure 2 shows a 
schematic model for breast tumor progression where there is a marked increase 
in genomic instability, genetic changes and cell death after telomere-induced 
crisis (DePinho and Polyak, 2004).  
 
Figure 3: Changes in cells during carcinogenesis 
 
Adapted from DePinho and Polyak, 2004. 
 
Cellular immortality alone is not enough to warrant tumorigenicity. 
Environmental cofactors which include chemical carcinogens and viral 
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infections are needed to effect additional genetic aberrations which results in 
the ability to create a microenvironment for the transformed cells.  
 
2.3.2. Genes and cancer 
Carcinogenesis involves the deregulation of cell cycle. The 2 groups of 
genes which regulate cell cycle include the proto-oncogenes and tumor 
suppressors. The former increases proliferation rate while the latter inhibits it. 
As such, most of which produces short-lived transcript which suggest a tight 
regulation of their expression (Mercola and Welsh, 2004). 
One mechanism proposed for activation of proto-oncogenes is gene 
amplification. This results in increased gene expression which results in large 
increase in message and protein levels (Ethier S, 2003). Oncogenes are altered 
versions of normal proto-oncogenes which regulate normal cell growth and 
differentiation. Many of these proto-oncogenes proteins are involved in signal 
transduction processes in the cell (Kang and Park, 2001). One of the most 
studied genes is the c-myc amplification in a number of cancers. However, 
there is evidence that suggest that gene amplification alone may not be the only 
explanation for overexpression of some genes at protein level. Example would 
be a recent report on TPD52 in which studies suggest that a combination of 
gene amplification and androgen stimulation likely contributes to the up 
regulation of the gene (Rubin et al, 2004). This reinforces the argument that 




Tumor suppressors proteins are frequently involved in the inhibition of 
cellular proliferation. Deregulation of these would enable extended 
proliferation. Perturbation of p53 protein function is a common finding in 
human cancer. p53 is a transcription factor which is phosphorylated following 
DNA damage. p53 function to arrest cells in G1-phase in order to allow DNA 
repair and activation of apoptosis to eliminate cells with damaged DNA. One 
of its target, promoter of p21Cip1, leads to induction of p21Cip1 which leads to 
a stop in cell cycle progression (Kang and Park, 2001). There is interplay of 
various genes during cancer progression. One such example is that several 
transcription factors such as c-Myc and tumor suppressor gene e.g., p53 are 
able to control hTERT transcription when overexpressed suggesting a tight 
control of hTERT is needed to prevent deregulation of cell cycle. hTERT 
deregulation has been shown to implicate in cellular immortalization. Indeed, 
both oncogenes and tumor suppressors are frequent targets of viral proteins to 
allow increase proliferation for viral particle propagation. In some cases, 
integration of viral genome may occur which predisposes the host to genetic 
aberrations which in turn may lead to viral induced cancers. 
 
2.4 Viral induced cancers 
Viruses results in transformed host cells which occur following insertion 
of viral nucleic acid into host’s DNA resulting in mutations in the two classes 
of human genes mentioned before; the proto-oncogenes and tumor-suppressor 
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genes. Table 1 shows a few examples of viruses causing different types of 
cancers.  
 
Table 1: Types of virus-induced cancers 
Virus Types of cancer 
HTLV-1 Adult T-cell leukemia 
HPV Squamous cell and genital carcinomas 
Hepatitis B  and C 
virus 
Hepatocellular carcinoma 





Human herpes virus 
B 
Kaposi’s sarcoma 
Simian Virus 40 Broad range including mammary and salivary 
glands, pancreas, prostate, liver, lung, kidney, 
intestine, brain, choroids plexus, lens of the eye, 
bone, smooth muscle, cartilage and lymphomas 
 
 
2.5 HPV  carcinogenesis 
Of the three causative molecular mechanisms of cervical cancer, two are 
associated with HPV. One is the effect of the viral oncogenes E6 and E7; 
another would be the integration of the viral DNA into chromosomal regions of 
tumor phenotype (Ledwaba et al, 2004). HPV are small double-stranded DNA 
viruses which consist of a circular genome. 90% of all cervical cancers contain 
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HPV DNA. The genome contain 8 early genes and 2 late genes of which E6 
and E7 early genes has been demonstrated to be important for viral-induced 
carcinomas of genital tract as they cause the inactivation of p53 and 
retinoblastoma respectively. Inactivation of p53 by E6 has been shown to 
precede the development of tumors with a fully malignant and invasive 
phenotype. E7 binding to pRB results in inactivation of pRB which results in 
hyperproliferation, but not immortalization of cells and tumorigenesis. (Chow 
et al, 2000; Stoler, 2000; Mantovani and Banks, 2001). E7 also binds and 
activates cyclin complexes such as p33-cyclin dependent kinase 2, which 
control progression through the cell cycle. HPV replicates only within the host 
cell’s nucleus, but the mechanism by which HPV transform cells is unclear. 
Most studies focus on HPV-16 and HPV-18, the viruses most frequently 
associated with anogenital carcinomas. Variations in carcinogenic potential 
results from the capacities of E6 and E7 proteins to interact with and alter or 
destroy key cell cycle regulatory molecules (Bosch et al, 2002). As mentioned 
earlier, HPV alone is not sufficient to progression to cervical cancer. 
Additional environmental, behavioral, immunological and genetic factors must 
be implicated in the pathogenesis and progression of cervical carcinogenesis. 
Recent evidence that HPV E6 and E7 oncoproteins induce chromosomal 
abnormalities resulting in genomic instability suggesting downstream effect of 
infection to carcinogenesis (Duensing and Munger, 2004). Cellular immune 
surveillance has been shown to be important in the control of HPV infection. 
Presentation to T cells of target viral peptides is though to influence the host 
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response and clinical outcome of HPV infection (Beutner KR, and Tyring S. 
1997). It has been suggested that the viral persistence, viral load and genetic 
predisposition are criteria involved in the pathogenesis of cervical cancer 
development. 
Table 2: HPV Gene Products and Their Function 
Gene Function 
E1 Initiation of viral DNA replication 
E2  Transcriptional regulation/DNA replication 
E3 Unknown 
E4 Alteration of mitotic signals 
E5 Transforming protein, interacts with growth factor receptors 
E6 Oncogene, binds to p53, leading to degradation 
E7 Oncogene, inhibits pRb, p107 and p130 
E8  Unknown 
L1 Major capsid protein 
L2  Minor capsid protein 
Adapted from http://www.mf.uni-lj.si/acta-apa/acta-apa-02-3/derma3-2cl.html 
 
2.5.1. HPV integration into human genome 
 The HPV genome replicates as an extra chromosomal episome or 
plasmid in benign HPV-associated lesions. However, the viral DNA is often 
integrated into the host’s chromosome in malignant HPV associated lesions. 
Viral integration results in lifetime persistence of certain viral genes and 
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increases the risk of cancer. It has been shown that the viral integration into 
host genome is the necessary event for the keratinocytes immortality 
(McGlennen 2000). The 1991 Couturier et al report  shows integration of HPV 
in cellular genomes near myc gene in genital cancers. This was found to be the 
case in most invasive genital carcinomas as compared to intraepithelial 
neoplasia where HPV DNA is detected most commonly as episomal molecules. 
This finding suggests a mechanism which may result in alteration of gene 
structure or overexpression of proto-oncogene.. Recently, human telomerase 
reverse transcriptase, hTERT, gene has been shown to be another target site for 
viral integration (Ferber et al, 2003). Viral integration occurs throughout the 
host genome, leading to the presumption that there are no preferred sites of 
integration (Ferber et al, 2003b). However studies by Thorland et al in 2000, 
showing integration into genome to be non-random with HPV 16 integration to 
frequently occur at common fragile sites suggesting presence of chromosome 
‘Hot Spots’ for viral integration. Ferber et al supported this finding by showing 
a preferential integration of HPV 18 near the c-myc locus in cervical 
carcinomas suggesting a nonrandom integration process. Another study by 
Ferber et al in 2003b involving the hTERT gene cited above supports the 
hypothesis of a nonrandom integration of viral genome and that the sites of 
integration may play an important role in carcinogenesis. HPV genomes 
attached to the host chromatin via E2 protein and replicate at a steady state, 
once for every cell division. During this process of integration, the viral 
genome breaks at E1 and E2 regions, never at the E6 and E7 region. The loss of 
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E2 results in the loss of E6 and E7 regulation. This allows the overexpression 
of E6 and E7 (zur Hausen, 1996). These proteins would continue to stimulate 
cells to ignore the DNA damage which have been accumulating and produce 
clones with extended lifespan. In addition, Pett et al 2004 showed high level of 
chromosomal instability upon HPV16 integration in cervical keratinocytes. 
 
2.5.2. Chromosome “hotspots” for integration and their 
implications 
As suggested above, the sites of integration may constitute genes 
involved in the regulation of cell cycle. Recent implication of HPV integration 
in hTERT genes further support the resulting immortalization of these cell 
clones indicating a directed integration into chromosomes “hotspots” which are 
probe to chromosomal breakage. The mechanism on the number of additional 
independent mutations or deregulation of genes and cell cycle needed for these 
cells to transform to full malignancy is still under investigation. Similarly, the 
apparent “recognition” of chromosomal hotspots has not been investigated. 
Perhaps isolation of genes involved in integration sites would provide a clearer 








2.6  RNA interference as a tool for cancer research 
RNAi is a process in which short 21-mers double-stranded (ds RNA) 
homologous to a specific gene post-transcriptionally silence or knock down the 
gene expression (McManu et al, 2002). Figure 3, adapted from McManus et al, 
2002 shows how short interfering RNAs (siRNA) which consist of 19bp duplex 
which is gene specific with 2nt 3’ overhang is recognize by a RNA interference 
silencing complex to guide mRNA cleavage and hence mRNA degradation. 
The siRNA mimics cellular products of Dicer-RDE-1 complex which processes 
long dsRNA to siRNA. RNAi has been shown to be able to induce degradation 
of target mRNA in the cytoplasm and has been suggested to also induce 
degradation during the process of nuclear mRNA export. True nucleoplasmic 
mRNAs or pre-mRNAs are however resistant to RNAi degradation (Zeng et al, 
2002). The natural function of RNAi and co suppression is thought to be 
protection of the genome against invasion by mobile genetic elements such as 
transposons and viruses. It is regarded as a posttranscriptional gene silencing 
regulatory process (Tuschl T, 2001). RNAi knockout and knockdown 
experiments in mammalian cells to elucidate gene function have been shown in 
gene targets such as CD4, CD8, CP110 etc (McManus MT et al, 2002). What 
determines the success of silencing would be the choice of oligo types, such as 
plasmid or chemically synthesized (Leirdal et al, 2002), oligo sequence (Brown 
et al) and the type of transfection reagent (McManus MT et al, 2002). RNAi 
has also been used in HeLa cells with sequence targeted to the E7 region of 
bicistronic E6 and E7 mRNA reducing expression of E6 and E7 in HeLa cells 
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which has been transformed with HPV18. This study shows that RNAi 
inhibited cellular DNA synthesis and induced morphological and biochemical 
changes characteristic of cellular senescence rather than apoptosis. The 
advantage of RNAi specificity without provoking a nonspecific interferon 
response, suggest a possible therapeutic use for RNAi in HPV related diseases. 
(Hall and Alexander, 2003). However, the molecular mechanism is still under 
investigation. Further studies are necessary before the use of RNAi for therapy 
could be considered. With the association of HPV and cervical carcinoma 
development, RNAi would serve as a valuable tool in elucidating the possible 
mechanisms for HPV induced carcinogenesis. The challenge here would be to 
target genes involved in this process. RNAi libraries which are increasingly 
available would enable investigations in this aspect. 
The limitation of this technique would be the non-specific antiviral 
interferon (IFN) pathway activation which affects cellular behavior 
independent of targeted gene. In addition, it has been reported that RNAi can 
also induce non-specific effects on untargeted protein levels independent of the 
IFN pathway (Scacheri et al, 2004). Hence careful interpretation and necessary 
controls are needed for conflicting results generated via this technique. 
Literature Survey 
 23
Figure 4: RNA interference mechanism  
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Figure 5: Flow chart of gene characterization 
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3.1. Mammalian cell tissue culture 
Cells were thawed in 37ºC water bath by gentle agitation. Vial was 
decontaminated by dipping in 70% ethanol before transferring vial contents to 
centrifuge tube with 10ml media. Cells were pelleted at 125 g for 5 min. 
Supernatant was discarded and resuspended in 5 ml media and transferred to 
25 cm3 tissue culture flask. 
For monolayer, culture media were removed and discarded. Cells were 
then rinsed with 1X PBS pH 7.4 (Appendix 1) before adding 0.5 ml trypsin. 
Trypsin was removed when cells started to lift off and appropriate media was 
added to cells and transferred to a new flask. Suspension cells were collected 
at 125 g for 5 min before rinsing with 1X PBS pH 7.4. Appropriate media was 
then added to cells and transferred to a new flask. 
Cells must be 90%-100% confluent and not more than 2 days old before 
cell collection. Monolayer cells were scrapped followed by centrifugation 
while suspension cells were directly collected by centrifugation. Supernatant 
was discarded and resupended in 1.5 ml of appropriate freezing media (growth 
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TABLE 3: List of cells with respective growth media used 
Cell Line Type* Media 
1. MOLT-4 T-lymphoblastic leukemia S RPMI 
2. HeLa  cervical carcinoma M DMEM
3. PLC/PRF/5 hepatocellular carcinoma M DMEM
4. MRC-5 fetal lung M MEM 
5. MCF7 breast adenocarcinoma M DMEM
6. Prostate Normal M PrEGM
7. Mammary Normal M MEGM
8. DU-145 Prostate carcinoma M MEM 
* S denotes suspension cell line while M denotes monolayer. 
 
3.2. Gene isolation 
Initial genomic gene isolation approaches such as positional cloning 
involved the comparative use of physical maps, which are mainly with genetic 
markers of known distances in base pairs apart, with linkage map, which is 
made up of distances measured by recombinant frequency (Lewin, 1997). 
Other methods include the detection of the presence of CpG islands, which are 
believed to mark 5’ end of transcriptionally active DNA sequences (Larsen et 
al, 1992), cDNA selection of YAC clones library to obtain genomic region of 
interest (Lovett, 1994) and “inverse genetics" whereby the protein of interest 
has been purified, but the gene that encodes that protein has not been identified. 
Thus using the protein sequence, one can then synthesized all possible coding 
Materials and Methods 
 29
sequence and use Southern blot for gene isolation (Robert, 2003). However, 
these methods are laborious and time consuming.  
For ease of gene identification, ESTs provide the answer for rapid gene 
scanning amidst the huge genome information. ESTs are expressed sequence of 
a gene. ESTs otherwise known as cDNA fragments are also useful for the 
annotation of physical maps, and function as handles for the classification of 
multigene families (Adams et al, 1991; Sim and Chow, 1999). They are 
isolated via use of mRNAs reversed transcribed into cDNAs. ESTs have the 
advantage of stability over mRNAs and they give an indication on the gene 
expression level and nature of the transcript such as splice variants (Tan et al, 
2003). Once an EST is isolated, nucleic acid hybridizations such as northern 
hybridization or RNase protection assay are used to detect the specific mRNA. 
But the sensitivity may not be sufficient to detect low levels of the expression 
of certain genes. Hence the use of RT-PCR is frequently used as a replacement. 
As more and more genes are isolated and studied, the usual belief that 
mammalian genes contain introns is also slowly changing. The only drawback 
of RT-PCR is the presence of false positive results due to possible 
contamination from genomic DNA. The problem of genomic DNA 
contamination becomes a big issue for intronless gene. How does one 
differentiate intronless genes with genomic DNA? To overcome the problem of 
false positive and to detect gene expression of an intronless gene, a highly 
sensitive detection system known as NASBA can be used. NASBA is an 
isothermal nucleic acid amplification reaction which uses a specific primer pair 
one of which contains a T7 promoter, AMV reverse transcriptase, E.coli. 
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RNase H and T7 RNA polymerase. NASBA achieve selectivity for ssRNA by 
use of initial denaturation of nucleic at 65°C which prevents denaturation of 
dsDNA followed by reverse-transcription at 41°C (Heim et al, 1998). Another 
method known as rapid amplification of cDNA ends (RACE) in which mature 
mRNAs are used as priming sites for elucidation of full-length cDNA.  
 
3.2.1. Genomic DNA Isolation 
Cells were grown to confluency with their respective growth media 
before being scrapped and harvested by centrifugation at 1500 rpm for 5 min at 
4°C. Cells were then washed thrice with 1X PBS before incubation with 4 ml 
of SSE (Sodium acetate, SDS, EDTA) extraction buffer (Appendix 2) for 5 
min. After which 1 volume (V) of SSE equilibrated phenol (Appendix 2) was 
added and shake gently for 5 min. Mixture was then spun at 3500 rpm for 5 
min at 4°C. The upper phase was recovered and added to 1 V of 
chloroform/isoamyl alcohol (25:1) and shake gently for 5 min. Mixture was 
then spun at 3500 rpm for 5 min at 4°C. The upper phase was recovered and 
DNA was precipitated overnight with 2 V absolute ethanol and 1 V of 4 M 
LiCl at -20°C before centrifugation at 14 000 rpm for 20 min at 4°C. 
Supernatant was discarded and pellet was washed with 1 ml 70% ethanol prior 
to drying before resuspension in 100 ul 1X TE (Appendix 2). 
 
3.2.2. Total mRNA Preparation 
Cells were grown to confluency with their respective growth media 
before being scrapped and harvested by centrifugation at 1500 rpm for 5 min at 
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4°C. Extraction of total cytoplasmic RNA was carried out with modifications 
using the method described by Gough (1988). Briefly, cells were washed thrice 
with 1X PBS and resuspended in 200 ul RNA extraction buffer A (Appendix 
2). After which, vortexing and spinning at 1000 rpm for 5 min at 4°C was 
carried out to separate cytoplasmic lysate from nuclear pellet. Cytoplasmic 
lysate was transferred to a new tube with 200 ul RNA extraction buffer B 
(Appendix 2). After vigorous vortexing, 200 ul of TE-equilibrated phenol 
followed by 200 ul of chloroform/isoamyl alcohol (49:1) was added. Tube was 
vortex then spun at 14,000 rpm for 2 min at 4°C. Supernatant was then 
transferred to new tube and total cytoplasmic RNA precipitated using 1 V 
100% ethanol and incubated 1 hour at -20°C before centrifugation at 14,000 
rpm for 20 min at 4°C. Pellet was washed with 1 ml 70% ethanol prior to 
drying before resuspension in 100 ul double distilled H2O (treated with diethyl 
pyrocarbonate, DEPC). Spectrophotometric readings were taken at 260 nm and 
280 nm using a Shimadzu UV160 spectrophotometer. The concentration of 
RNA was subsequently standardized to 100 ng/ul. RNAsin (Gibco #15518-
012) was added to a final concentration of 1 U/ul. The RNA was stored at -
80°C until further use. 
 
3.3. Primers location and use 
Primers were synthesized by either GENSET Singapore Biotech. Pte 
Ltd, Operon Technologies Inc., or 1st Base. All primers were made to 100 uM 
and the working solution for PCR and cycle sequencing reactions were 10 uM 
and 1 uM respectively.  
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Table 4: List of primers and their respective cDNA positions  
Primer Sequence Position Use of primers 
TR4.1 5’ ACT CCT GAG CTC AGG CAA TC 3’ 1368-1387 Intron/Exon mapping, 
expression studies, RACE  
library screening 
TR4.2 5’ ATT TCT ACC CCA GGA GTC AGG TC3’ 1277-1299 Intron/Exon mapping, 
expression studies (nested) 
TR1 5’ CAT TCT CCA TGG TGG CTA CCC TG 3’ 1102-1125 RACE, Intron/Exon mapping 
TR2 5’ CTG TGG CCA AGC CTG ACA TCC AC 3’ 1136-1157 RACE, Intron/Exon mapping 
TR3 5’ TCT GAC AGG CCA TCG TCA GCT GC 3’  714- 736 Sequencing of full length cDNA 
TR4 5’ TCT GAT CGA GGG CTC AAG AC 3’ 2350-2369 Sequencing of full length cDNA 
TR5 5’ TCT CCT CAA GGC AGC TGG AG 3’ 1968-1987 Sequencing of full length cDNA 
TR6 5’ AGA GGC TCA GGT CCA AAG C 3’  394- 412 Sequencing of full length cDNA 
TR7 5’ AAA ACG CGG TAC GGA ACT TCT C 3’ 1806-1827 Sequencing of full length cDNA 
TR8 5’ TTT ACC GGA GCT CAC ACG GCT AC 3’ 2648-2670 Generation of FISH probe 
TR9 5’ TGA AAC ACA CCC TTC TCG 3’ 2546-2563 Generation of Northern probe 
TF1 5’ AGC CAC CAT GGG AGA ATG TC 3’ 1108-1127 RACE, Intron/Exon mapping, 
RACE library screening 
TF2 5’ TGG ATG TCA GGC TTG GCC ACA GG 3’ 1136-1158 RACE, Intron/Exon mapping 
TF3 5’ ACA TGC CTG TAG TCC CAG CTA CG 3’ 1462-1480 Sequencing of full length cDNA 
TF4 5’ TCC ACC TTA CGT AGC CGT GTG AG 3’ 2638-2660 Sequencing of full length cDNA 
TF5 5’ TTG TCC AGC ATT ACA AGA GCA CC 3’ 860-882 Intron/Exon mapping, 
expression studies 
TF6 5’ TCT TGA GCC CTC GAT CAG AG 3’ 2351-2370 Sequencing of full length cDNA 
TF7 5’ TAC AGG GAG GAA CAA GGA GAA AC 3’ 1000-1022 Intron/Exon mapping, 
expression studies (nested) 
TF8 5’ TCC GCT GTC TAC CCA TG 3’ 1901-1917 Sequencing of full length cDNA 
TF9 5’ TGC AAC CCA AAC TCG AC 3’ 2462-2478 Sequencing of full length cDNA 
TF10 5’ ACC ATA GAC AAC TGC CAC TCA CTG 3’   34- 57 Generation of FISH probe  
TF11 5’ ACA TCC CCA TCT CAC AG 3’  124- 140 Generation of Northern probe 
TF12 5’ AAG TCT GAG GCT CTG 3’  565- 579 Sequencing of full length cDNA 
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3.4. Rapid amplification of cDNA ends (RACE) 
Marathon-Ready MOLT-4 and human fetal lung (Clontech) cDNA 
libraries ligated with adaptor oligonucleotides were used as templates for 
RACE reactions. Based on the original MOST-1 EST, gene-specific primers 
TF1 (nt 1108-1127) and TR4.2 (nt 1299-1277) were designed. Before RACE, 
PCR was performed with these primers to confirm that the cDNA libraries 
contained the cDNA of interest. Primers TR4.2 and TF1 were individually 
paired with the adaptor primer AP1 in initial RACE experiments via long-
distance PCR using Advantage 2 polymerase (Clontech). Nested primers TR1 
(nt 1125-1102) and TF2 (nt 1136-1158) were then paired with the adaptor 
primer AP2 in subsequent RACE to obtain the 5′ and 3′ RACE fragments, 
respectively. Thermal cycling conditions were 94°C for 30 sec, followed by 25 
cycles each of 94°C for 5 sec and 68°C for 4 min. The RACE products were 
cycle-sequenced as described below.  
 
3.5. Cycle Sequencing 
ABI PRISM BigDye terminator cycle sequencing ready reaction kit was 
used with 30-90 ng DNA and 3.5 uM primer. Reaction mix was topped to 20 ul 
with water. Thermal cycling conditions were 25 cycles each of 96°C for 10 sec, 
50°C for 5 sec and 60°C for 4 min. After which, ethanol precipitation was 
carried out. Contents were dried and sent for sequence analysis with ABI 
PRISM 377 DNA sequencer (PE Applied Biosystems). 
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3.6. Bioinformatics Analysis of MOST-1 gene  
Bioinformatics provide prediction softwares and faster database servers 
in user friendly-environment. Various programs for different purpose have 
been produced for different studies such as genomic analysis, computational 
translation and putative protein analysis. These have accelerated information 
sharing and technology transfer. Listed below are several programs used in this 
study. 
  




Sequence alignment for DNA and protein for 
human and model organisms 
Bioportal 
www.bic.nus.edu.sg  




Latest update on periodicals even before press 
ProtParam 
www.expasy.ch  
Analysis of computed/experimental protein 
sequence for prediction such as protein solubility, 




Motif  and domain search, globularity prediction, 
protein structure prediction 
SUMOplot prediction 
http://www.abgent.com/sum
Attachment sites of SUMO protein (11kDa) 
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oplot.html  
NetOGlyc 2.0 Server 
http://www.cbs.dtu.dk/servic
es/NetOGlyc/  
Mucin type GalNAc O-glycosylation sites in 
mammalian proteins. 
DNASIS and DnaSTAR Software analysis packages for sequence analysis, 
protein analysis, sequence alignment and  
chromatogram overlay 
 
Nucleotide analysis was carried out using GCG analysis (bioportal) and 
BLAST program  while putative amino acid sequence analysis and motif 
searches were performed using bioinformatics softwares such as ProtParam, 
Predictprotein, SUMOplot and NetOGlyc 2.0 Server. These programs 
allows the prediction of post-translational modification. The type of 
modification allows one to further understand the role of the protein in the 
cells. Post-translational modifications include the following: 
• proteolytic cleavage of inactive proproteins, eg pancreatic enzymes, and 
signal peptide from preproteins 
• glycoproteins, in which oligosaccharides such as glucose, galactose, 
fructose, GalNAc, GlcNAc and NANA are covalently attached to 
proteins, either via O-glycosidic or N-glycosidic bonds. N-glycosidic 
linkage being the predominant attachment to glycoproteins of 
mammalian through the amide group of asparagines within a consensus 
sequence N-X-S (T) where X is any amino acid except praline. O-
glycosidic linkage is to the hydroxyl of serine, threonine or 
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hydroxylysine (generally only found in collagens). Most secretory or 
plasma membrane bound proteins are modified by carbohydrate 
attachment and it is normally the extracellular portion of the protein that 
is modified. Attachment of carbohydrate to intracellular proteins is rare 
but confers unique functional activities and occurs via O-linkage and 
involves the attachment of GlcNAc to serine or threonine residues. 
Several transcription factors and RNA polymerase II have been shown to 
be modified by O-GlcNAc linkage, 
• lysosomal targeting of enzymes are directed by a specific carbohydrate 
modification in which GlcNAc-1-phosphate is added to the carbon-6 
hydroxyl group of one or more specific mannose residues that have been 
added to these enzymes. Removal of GlcNAc leaves mannose residues 
phosphorylated as Man-6-P which is then able to bind to a specific Man-
6-P receptor that is present in the membranes of the Golgi apparatus 
which upon binding will target proteins to the lysozyme, 
• acylation occurs when N-termini methionine is hydrolyzed and an acetyl 
group is added. Some protein have 14 C myristoyl group added which 
allows association with membranes,  
• methylation occurs at lysine residues of some proteins for eg, 
calmodulin, 
• phosphorylation is one of the most common protein modification that 
occurs in animal cells and is normally regulatory in nature. As such, 
these modification is transient and occurs at serine, threonine and 
tyrosine residues ratio being 1000:100:1 respectively, 
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• sulfation is the permanent modification of proteins at tyrosine residues 
that is normally necessary for biological activity, 
• prenylation is the addition of 15 C farnesyl group to cysteine residues at 
C-terminus of protein in a thioether linkage (C-S-C) at consensus 
sequence of CAAX where C is cysteine, A is any aliphatic amino acid 
except alanine and X is the C-terminal amino acid. Numerous G-
proteins of signal transduction cascades have γ-subunits with this 
modification,  
• vitamin C and K dependent modifications occur when enzymes carrying 
out the modification require either as a cofactor. Proline and lysine 
hydroxylation and carboxy terminal amidation requires vitamin C as 
cofactor while carboxylation of glutamine residues requires vitamin K.  
 (http://www.indstate.edu/thcme/mwking/proteinmodifications.html) 
Once the protein modification is predicted, experiments can then be 
designed to verify the prediction. As more proteins are found to have different 
active states, function and localization depending on their post-translational 
modifications, there are also systems to study some of the more common 
modifications such as  
• signal peptide cleavage  which can be observed as a shift to a lower 
molecular weight upon SDS-PAGE analysis when the template is 
expressed in rabbit reticulocyte lysate in the presence of canine 
pancreatic microsomal membranes (Walter et al, 1983), 
• glycosylation can be observed with the use of enzymatic deglycosylation 
assays or antibody detection of oligosaccharides, 
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• acetylation inhibition with the addition of S-acetonyl CoA (Rubenstein. 
1981) and 3 mM EDTA to block phosphorylation (Nakamura. 1993). 
 
3.7. Organization of MOST-1 gene 
RNA is first modified in the nucleus after transcription by having a cap 
added on the 5’ end and a poly-A tail at the 3’ end. Splicing then occurs after 
which the now matured mRNA is transported through the nuclear pore to the 
cytoplasm where it is translated. Splicing occurs with introns having a GU-AG 
rule flanking its ends (Lewin, 1997). To determine the presence of exon or 
intron, primer pairs flanking 200-400 bp target fragments were designed based 
on the full length MOST-1 cDNA sequence derived from RACE. With these 
MOST-1 primer pairs, PCR products amplified from MOLT-4 genomic DNA 
and cDNA were sequenced, compared and subjected to Grail computational 
analysis. (http://compbio.ornl.gov/Grail-1.3).  
 
3.8. Chromosomal Localization of MOST-1 gene 
After obtaining the full length cDNA, chromosomal localization should 
be done to further understand the gene function. With the completion of the 
human genome project, chromosome mapping allows us to have an idea if the 
gene is present at a particular disease locus. Chromosomal position of MOST-1 
was mapped by fluorescence in situ hybridization (FISH), using a genomic 
probe of ~2.6 kb generated from MOLT-4 genomic DNA and primers TF10 (nt 
34-57) and TR8 (nt 2670-2648). The probe was then sent to SeeDNA 
(www.seedna.com) for hybridization. Chromosomal slides were prepared using 
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cultured lymphocytes isolated from human blood. Cells were synchronized and 
harvested. Cells were then mount onto slides using standard procedures of 
hypotonic treatment, fixation and air-dry. DNA probe was biotinylated with 
dATP and procedure for FISH detection were performed according to Heng et 
al., 1992 and Heng et Tsui, 1993. Assignment of FISH mapping data with 
chromosomal bands was achieved by superimposing FISH signals with DAPI 
banded chromosomes. The MOST-1 sequence was also subjected to 
computational analysis with the UniGene program 
(http://www.ncbi.nlm.nih.gov/UniGene) 
 
3.9. MOST-1 Expression  
Since the chromosomal location of MOST-1 is mapped to 8q 24.2, a 
locus gained in many cancers, expression studies such as screening of cells 
lines, tissues and biopsies, was done to further correlate the gene with the 
disease. Multiple tissue cDNA panels generated from poly(A)+ RNA of 16 
human adult tissues (0.8 ng each) (Clontech), and total mRNA (200 ng each) 
extraction were reverse transcribed to cDNAs from 19 human cancer and 2 
normal cell lines extraction as described above, were screened for MOST-1 
expression with PCR using primers TF5 (nt 860-882) and TR4.2. This primer 
pair flank a 440 bp fragment was performed using a profile of 95°C for 1 min, 
followed by 25 cycles each of 95°C for 30 sec, 60°C for 30 sec and 72°C for 30 
sec. A subsequent amplification was repeated using a 50× dilution of the first 
PCR product as template. To serve as controls for the human adult tissues and 
cell lines, housekeeping genes were also subjected to PCR using 
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glyceraldehyde-3-phosphate dehydrogenase (G3PDH)-specific primers (Abel-
Mageed et al., 1997), and/or HUEL gene-specific primers 5R2 (5′-
AAGTATGTAATGGAAAGTCGTG-3′) and R3 (5′-
AAGCATAAAGGTCTCTAGTTCTTCAGG-3′) (Sim and Chow, 1999). All 
reactions were performed in duplicates. 
 
3.10   Northern Blot analysis 
To verify the full length of gene and screening of tissues DNA, 
Northern analysis was carried out. Probe was generated by PCR and purified 
with Qiagen gel extraction kit. The DNA was then labeled with Redivue γ32P 
dCTP (Amersham pharmacia biotech) with MegaprimeTM DNA labeling 
system (Amersham pharmacia biotech). Briefly, 25 ng of DNA was incubated 
with 50 uM primers and heat at 95°C for 5 mins before spun down and cooled 
to room temperature. 10 ul of labeling buffer, 2 ul of enzyme and water was 
added to a final volume of 45 ul. 5 ul of Redivue γ32P dCTP was then added 
and incubated at 37°C for 60 mins. 5 ul of 0.2 M EDTA was then added to stop 
the reaction prior to purification via ChromaSpin columns (Clontech). Activity 
should be in the range of 1-2 x 107 cpm/ul. MTN blot (Clontech) was then 
prehybridize in ExpressHyb solution at 37°C for 30 mins. Probe was then 
added and incubated with the blot at 60°C for 60 mins. Blot was then washed 
with wash solution 1 (See Appendix 2) thrice with 10 min incubation at room 
temp each and then with wash solution 2 (See Appendix 2) thrice with 10 min 
incubation at 50°C. Blot is then expose to X-ray film O/N in -70°C. 
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3.11   Semi-quantitative RT-PCR analysis 
Since chromosomal location mapped MOST-1 to 8q24.2, a region found 
by comparative genomics to be amplified in ~70% of prostate and 50% of 
breast cancer tissues, a screen of breast and prostate biopsies was carried out. 
Total RNAs, previously isolated via needle biopsy and graded according to the 
Nottingham modified WHO criteria, from 27 pairs of snap-frozen invasive 
ductal breast cancer and adjacent normal tissue samples were used (Jin et al., 
2000, 2001, 2002) (Appendix 5). After reverse transcription, 80ng of cDNA 
sample was subjected to PCR amplification using primers TF5 and TR4.2 at 
95°C for 30 sec, followed by 35 cycles each of 95°C for 30 sec, 65°C for 30 
sec and 72°C for 1 min. Semi-quantitative analysis of MOST-1 mRNA was 
facilitated by concurrent RT-PCR of the G3PDH housekeeping gene (Abel-
Mageed et al, 1997). A prior PCR cycle optimization was conducted to ensure 
that all reactions remained in a linear region (by removal and analysis of 
samples at 15, 20, 25, 30, 35 and 38 cycles). The resultant RT-PCR products 
were electrophoresed along with DNA markers in agarose gels stained with 
ethidium bromide, visualized under UV, and analyzed by densitometric 
scanning using a GS-700 Imaging Densitometer and Quantity One software 
(Bio-Rad, Hercules, CA). The level of MOST-1 expression was quantified by 
calculating the ratio of the intensity of each RT-PCR product of MOST-1 to 
that of G3PDH (Jin et al, 2000, 2001, 2002). Relative MOST-1 expression was 
further presented as the differential expression between corresponding tumor 
(T) and normal (N) tissues as follows: overexpression in tumor tissue compared 
with matched normal tissue (T>N); decreased expression in tumor tissue 
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compared with matched normal tissue (T<N); and no difference (T=N) (Xu et 
al, 2000). All reactions were performed in triplicate or duplicate, and mean 
values derived.  
 
3.12 Real time PCR analysis  
DNA were extracted from randomly selected, paraffin-embedded tissue 
sections of normal, hyperplastic and malignant prostatic biopsies (Appendix 5) 
using buffer comprising 0.5 M Tris, 10 mM NaCl, 20 mM EDTA, 1% SDS (pH 
9.0) and proteinase K. This was accompanied by phenol/chloroform/isoamyl 
alcohol extraction and ethanol precipitation. DNA samples were reconstituted 
to the same concentration of 100 ng/µl, and 100 ng of each sample was used for 
amplification. Real-time PCR was performed with primers TF1 and TR4.2 
using the iCycler iQ SG-1 quantitative PCR reaction buffer kit (Bio-Rad) and 
LightCycler - DNA Master SYBR Green I (Roche Diagnostics), at 95°C for 4 
min followed by 40 cycles each of 95°C for 30 sec, 65°C for 30 sec and 72°C 
for 1 min. Also included was the amplification of the G3PDH housekeeping 
gene (Abdel-Mageed et al, 1997). All reactions were performed in triplicate or 
duplicate, and mean values derived. Real-time PCR conditions were optimized 
by varying MgCl2 concentrations between 1.5 mM and 5 mM. Different 
starting amounts of template were also used for validation of amplification 
efficiency. For each sample, the threshold cycle (CT) values for both MOST-1 
and G3PDH were determined, and the difference between their CT values 
(∆CT) was calculated as recommended by the manufacturer of the real-time 
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PCR kit (Bio-Rad). The mean ∆CT values of each category of normal, 
hyperplastic, low, intermediate and high grade carcinoma samples were 
calculated using SPSS for Windows (release 10.0.5). These mean ∆CT values 
were then subjected to analysis by multiple comparisons, and the p values of 
significance between their differences were computed. Acting as the reference, 
the mean ∆CT of normal tissue samples was compared against the mean ∆CT 
values of hyperplastic samples and carcinomas of varying grades in order to 
obtain the relative DNA levels presented as a numerical-fold change for each 
category of prostatic neoplasia (Xu et al, 2000). 
 
3.13 Raising of polyclonal antibody 
3.13.1 Design of synthetic peptide 
Rabbit polyclonal anti-MOST-1 was made by using synthetic peptide 
Ac- TGPEQSDICHTGSEAR-NH2 (aa 19-34), corresponding to the predicted 
hydrophilic and antigenic regions of MOST-1, conjugated to Diphtheria toxoid 
(Mimotopes Pty. Ltd, Australia, http://www.mimotopes.com).   
3.13.2 Generation of antibody 
Polyclonal antisera were raised in three rabbits by immunizing with 
synthetic peptides. Peptide conjugate were mixed with Freud’s incomplete 
adjuvant 1:1 ratio until a thick, white emulsion. The peptide conjugate was 
injected at week 3, 5 and 8 after acclimation (Week 1). Rabbits were bled at 
weeks 2 (pre-immune), 7 and 10 (hyper-immune bleed). Bleeds were then 
incubated at 37°C for 1 hour followed by 4°C O/N. Serum was drawn and 
residual red blood cells were spun down at 200 g for 5 min. Serum was then 
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subjected to dot blot assays. Antibody characterization was done using dot blot 
analysis to select for positive serum before affinity purification. 
Batchwise affinity purification procedure was carried out according to 
manufacturer’s recommendation. Briefly, specific peptide covalently coupled 
to thiopropyl-sepharose 6B gel syringe column was washed 5 times with 8 ml 
PBS pH 7.4 each time. 5 ml of serum followed by 3 ml of PBS were drawn into 
the syringe before sealing nozzle. Syringe was mixed O/N at 4°C. Solution was 
then expelled from the syringe and washed with PBS 5 times as above followed 
by 3 washes with saline. 7 ml of 0.1 M glycine/HCl buffer pH 2.5 were mixed 
with gel slurry for 1 min before expulsion from syringe. Elution was repeated 2 
more times followed by 2 washes with saline.  Procedure was repeated with 0.1 
M glycine/NaOH buffer pH 11.5. All solutions were pulled and pH of antibody 
solution was adjusted to 7.0 using 5% phosphoric acid. Antibody solution was 
then concentrated using AMICON Ultrafiltration apparatus model M3 to 5 ml. 
Antibodies was then aliquot and stored at -20°C. 
 
3.13.3 Dot Blot analysis 
Conjugated and unconjugated peptides (500 mM) were dot on 
nitrocellulose membrane 5 times each with 1ul of peptide mixture. Membrane 
was then block O/N at 4°C with blocking solution (Appendix 3) before wash 
with TBST (Appendix 3) 10 min twice. The collected serum was then added in 
1:1000 dilution and incubated at room temperature for 1h before washed twice 
with TBST buffer, followed by incubation with biotinylated goat anti-rabbit 
IgG (diluted 1:3000 with TBST) (Biorad) 1 hour at room temperature, washed 
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twice with TBST buffer and reacted with streptavidin conjugated with alkaline 
phosphatase (diluted 1:10, 000 with alkaline phosphatase buffer) (Appendix 3).  
Immunoreactive dots were visualized by color development with NBT/BCIP 
substrates (Appendix 3). 
 
3.14 Polyclonal antibody verification  
For verification of affinity purified antibody, Western analysis was done 
on in vitro translated recombinant MOST-1 protein. 
 
3.14.1 In vitro translation 
MOST-1 was cloned into p-Bluescript SK II vector (Stratagene) and 
used in TNT® T7 quick coupled transcription/translation system (Promega).  In 
vitro TNT experiments were carried out with and without RedivueTM L-[S35] 
labeled methionine (Amersham Pharmacia Biotech). Briefly, TNT mix with 1 
ug plasmid containing MOST-1 insert and 1 mM labeled or unlabelled 
methionine was incubated at 30°C for 90 min. 5 ul of the translated products 
were then ran on a 10% SDS-PAGE gel.  Western detection as described below 
was done on unlabeled reaction mix while labeled reaction mix lane was 
exposed to X-ray film O/N and developed. 
 
3.14.2 Differential treatment for aggregates 
As antibody only detects high molecular weight species of recombinant 
MOST-1, differential treatment of MOST-1 aggregates was done. TNT 
experiment with unlabelled methionine was carried out as above and products 
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were subjected to either 95°C for 5min, incubation with 2% SDS or both 
treatments. 5 ul of products or untreated rabbit lysate only were then 
electrophoresed in 10% SDS-PAGE gel before subjected to western analysis 
described below. No sample buffer was used to maintain non-reducing 
conditions. 
 
3.15 Protein Characterization 
Protein can be membrane associated or free in cytosol in the cells. 
Proteins synthesized in the cytosol can remain there and function as individual 
catalytic centers, or as macromolecular structures constructed from cytosolic 
proteins, or as nuclear proteins in which after synthesis in cytosol they are 
transported through the nuclear envelope, or in cytoplasmic organelles such as 
mitochondria. The cytoplasm also contains the reticuloendothelial system 
which includes the endoplasmic Golgi apparatus, endosomes and lysosomes. 
Proteins that localize to these compartments are inserted into the ER and 
transported to their respective location via the transport system of Golgi 
apparatus. Secretory proteins are transported to the plasma membrane via the 
reticuloendothelial system before passing into the exterior of the cell. Short 
signal motifs are present on the proteins for protein trafficking. A summary of 
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Table 6: Cell signaling motifs 
Organelle Signal location Type Length 
Mitochondria N-terminal Amphipathic 
helix 
12-30 
Nucleus Internal Basic or bipartite 7-9 
Peroxisome C-terminal SKL 3 
(Adapted from Genes VI) 
Chaperones also play a role in protein localization as they maintain 
protein in an unfolded state before membrane passage so that it will fit into the 
available channel. Once in the organelles, a hierarchy of sequences will 
determine the location within the organelle (Lewin, 1997). Protein location also 
gives a hint of the possible changes that occur during functional vs. non-
functional state or disease and non-disease state. Such is in the case of src 
kinases, which have to be myristolyated and membrane bound before being 
able to induce cellular transformation. An example of this phenomenon is the 
study on v-fgr oncogene in which its subcellular localization is a factor for its 
ability to induce transformation (Baker et al, 1998). 
 
3.15.1 Total protein extraction 
Total protein extraction was prepared by culturing cells to 90% 
confluence before washing trice with cold PBS (pH 7.4). Lysis buffer I 
(Appendix 3) with complete protease inhibitor cocktail (Roche) was added and 
incubated on ice for 30 min with occasional mixing before centrifugation at 
14,000 rpm, 15 min, 4°C. The supernatant was harvested. 
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3.15.2 Fractionated protein extraction 
Subcellular fractions of cultured cells were prepared as previously 
described with modifications (4). Cells were cultured to 90% confluence 
before washing trice with cold PBS. Lysis buffer II (Appendix 3) with a 
complete protease inhibitor cocktail (Roche) and incubated on ice for 15 min 
with occasional mixing before centrifugation at 1000 rpm, 5 min, 4°C. The 
pellet representing the nuclear fraction was processed with Lysis buffer I as 
above. The supernatant was harvested and ultracentrifuged at 100,000 g, 1 
hour, 4°C. The resulting pellet representing the microsomal fraction was 
processed in the same way as the nuclear pellet. The supernatant containing the 
cytosol fraction was brought to final concentration of 1% sodium deoxycholate 
and 1% Triton X-100. 
 
3.15.3 Western Blot Analysis 
Fifteen ug of lysate obtained above was loaded per lane and subjected to 
12% polyacrylamide-SDS gel electrophoresis in Laemmli running buffer 
(Laemmli, 1970) and electroblotted  onto polyvinylidene difluoride (PVDF) 
(Roche) membrane in CAPS transfer buffer. Membranes were blocked for 1 
hour at room temperature and washed twice with TBST buffer. Each blot was 
incubated with primary antibody (diluted 1:1000 with TBST) (Biorad) O/N 
4°C, washed twice with TBST buffer, followed by incubation with biotinylated 
goat anti-rabbit IgG (diluted 1:3000 with TBST) (Biorad) 1 hour at room 
temperature, washed twice with TBST buffer and reacted with streptavidin 
conjugated with alkaline phosphatase (diluted 1:10, 000 with alkaline 
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phosphatase buffer) (Biorad). Immunoreactive bands were visualized by color 
development with NBT/BCIP substrates. BenchmarkTM protein ladder 
(Invitrogen Life Technologies) was concurrently run, transferred, cut, and 
stained with Coomassie Blue. Immunoreactive molecular masses were then 
estimated from logarithms graph obtained. 
 
3.15.4  Indirect Immunofluorescence 
Cells were cultured on 13 mm glass coverslips in 24-well microplates 
until 70% to 80% confluency, washed trice with cold PBS, fixed with 3% 
paraformaldehyde (PFA) for 10 min at room temperature, washed with PBS, 
permeabilize with 0.1% Triton-X 100 for 1 min, washed twice with PBS 
before quenching aldehyde groups with 5 mM NH4Cl in PBS. Cells were then 
blocked with 0.1% FCS in PBS for 30 min at room temperature before 
incubation with primary antibody (diluted 1:100 with blocking solution) O/N 
at 4°C in a humidified chamber. Cells were then washed with 3 changes of 
blocking solution over 30 min before incubation with FITC-conjugated goat 
anti-rabbit IgG antibody for 1 hour at room temperature (diluted 1:10 with 
blocking solution) (Pharmingen). After which, 3 washes with blocking 
solution and 1 wash with PBS were done before mounting coverslips on 
ethanol-cleaned slides and viewed using a Zeiss LSM 510 laser scanning 
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3.16 Cloning 
3.16.1. Preparation of competent cells 
Chemical competent cells were prepared by picking colony to grow in 5 
ml LB O/N at 230 rpm at 37°C. After which, 1:100 dilution was incubated at 
230 rpm at 37°C until OD600 = 0.5 to 0.6. Culture was then left on ice for 20 
min, spun down at 2 500 rpm for 15 min and resuspended in ½ volume cold, 
sterile 50 mM CaCl2 before incubation on ice for 20 min. Cells were spun 
down again and resuspended in 1/10 volume of 20% glycerol in 50 mM CaCl2. 
Cells were then aliquoted and stored at -70°C. 
 
3.16.2. Transformation 
Transformation was carried out by incubating 2 ul of ligation mix with 
40 ul of competent cells prepared above. Incubation on ice for 20 mins before 
heat shock at 42°C for 45 s and ice for 2 min. One ml LB (See Appendix 3) 
was added and culture was incubated at 230 rpm at 37°C for 1 h. Cells were 
then spun down and resuspended in 150 ul LB and plated out on LB selection 
plates.  
 
3.17 Cell synchronization studies 
Cell cycle is the universal process for cell reproduction. It underlies the 
growth and development of all living organisms. Hence the precision at which 
the events are executed will ensure the survival of the living organism. It is 
usually the loss of this precision which results in genomic instability which in 
turn leads to cancer formation. Cell cycle is defined as the period between two 
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mitotic divisions. The start being the interphase with mitosis being the actual 
division. Mitosis results in two identical daughter cells failing which will result 
in either duplication or loss of chromosomes. The cell cycle consists of 4 
phases, G1, S, G2 and M phase. There is a double of DNA content from G1 to 
G2 phase. Mitosis consists of 4 stages namely prophase, where chromosomes 
becomes visible as extended structures; metaphase, where bivalent 
chromosomes aligned on equator; anaphase where homologue pairs move to 
opposite poles and telophase where chromosomes reaches the poles and 
decondense into chromatin. All these are collectively known as mitotic figures. 
There are basically 2 cycle controls, the commitment to chromosome 
replication at G1 and the commitment to mitotic division at G2 phase. In 
addition, the cell cycle has many checkpoints which ensure correct duplication 
of cellular components. There are check points for division in G1 phase, DNA 
integrity at S phase and unreplicated DNA checks at G2 phase. The control of 
cell cycle proteins usually occurs via protein phosphorylation and 
dephosphorylation. Kinases which are responsible for phosphorylation, consists 
of a catalytic subunit called cyclin-dependent kinases (cdks) and a regulatory 
cyclin partner. It is the timing of activity of the various forms of cdk/cyclins 
that regulate cell cycle progression (Lewin Benjamin, 1997). CDKs mentioned 
above regulate the cell cycles by fluctuation during the cycle. CDKs have a 
catalytic protein kinase subunit and a regulatory cyclin subunit. These were 
found universally from yeast to mammals. CDKs are regulated through several 
mechanisms such as the availability of the cyclin regulatory subunit, the 
phosphorylation of the catalytic subunit and by the presence of inhibitory 
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subunits. Expression of these proteins are also regulated at both transcription 
and translation level. Lastly, degradation of these proteins involved the 
ubiquitin-mediated proteolysis. This shows a large number of proteins 
orchestrating in cell cycle progression and hence in cancer formation, a large 
number of protein have to be likewise deregulated. Cell synchronization is used 
to allow precise study of regulatory mechanisms of cell cycle. Common ways 
include the use of serum starvation and reversible inhibitors such as mimosine. 
Mimosine, a non-protein plant amino acid, is an effective inhibitor of DNA 
replication and is able to block cell cycle progression in late G1 phase prior to 
onset of DNA synthesis (Vackova et al, 2003 and Krude T, 1999). Cells can 
then be released and test product or treatment can be done. The cell cycle can 
then be analyzed with flow cytometry of propidium iodine stained cells or 
fluorescent conjugated intracellular antibodies which detects intracellular cell 
cycle proteins such as cyclins.  
 Since previous results show an increased in MOST-1 expression in 
cancer cells, experiment to investigate MOST-1 association with cell cycle was 
carried out using mimosine cell synchronization studies. Cells were grown to 
50% confluency and medium containing 0.5mM mimosine (Sigma) was then 
added and incubated at 37°C for 24 h. Medium was then removed and cells 
were washed with PBS and normal grown medium was added. Cells were then 
harvested at 0, 2, 4, 6, 8, 10, 12, 36, 48 h and subjected to immunofluorescent 
microscopy as described above or flow cytometry. 
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3.18 Overexpression and RNA interference studies 
Since MOST-1 expression levels has been associated with high grade 
breast and prostate biopsies, experiments were design to investigate the effect 




MOST-1 was amplified from HA-MOST1 using primers pcDNAF 
(5’CACCATGGGAGAATGTCCCCACC3’) and pcDNARev 
(5’CCATGTTGTCCAGGCTGGTCTCG 3’)  to give a product size 
encompassing the MOST-1 ORF of 297bp and cloned into pcDNA 3.1 
expression vector with V5 tag (Invitrogen).  Clones were sequenced to ensure 
that the protein was in frame with tag and was checked for expression via in 
vitro translation as described by manufacturers (Promega) followed by Western 
analysis. Cells were then transfected with lipofectamine 2000 (Invitrogen) 
according the recommendation. Timed extraction (12, 24, 36 and 48 h) of cell 
lysates followed by Western analysis using anti-V5-AP (Invitrogen) were done 
to optimized time of expression. After determination of time, cells were 
harvested for RT-PCR analysis using MOST-1 gene specific primers TR4.2 
and TF2 and housekeeping primers G3DPH. The cells were also subjected to 
cell proliferation assay via BrdU labeling (Clontech) and TUNEL assay 
(Clontech) described below. 
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3.18.2. RNA interference 
Duplex RNA from Dharmacon Inc, targeting the ORF start region was 
constructed with the following sequences: 5’-
UGUCCCCACCUCGUGGAUGdTdT-3’ and 5’-
CAUCCACGAGGUGGGGACAdTdT-5’. The oligonucleotides were annealed 
according to the Dharmacon protocol. 3 ul of 20 mM duplex RNA were used 
per 24 wells as recommended by manufacturer. As a control for the specificity, 
we used a scrambled ribo-oligonucleotide pair with the following sequences 5’-
GCGCGCUUUGUAGGAUUCGdTdT-3’ and 5’-
CGAAUCCUACAAAGCGCGCdTdT-3’. To test the cell lines for RNAi 
silencing, luciferase GL3-duplex with the following sequences 5’-
CUUAGCCUGAGUACUUCGAdTdT-3’ and 5’-
UCGAAGUACUCAGCGUAAGdTdT-3’ to co-transfect the cells using 
lipofectamine 2000 together with pGL3-control vector (Promega). Again, cells 
were subjected to cell proliferation assay via BrdU labeling (Roche) and 
TUNEL assay (Clontech) described below. 
 
3.18.3. Cell Proliferation assay 
To detect cell proliferation, there are several methods which use 
detection of proliferating antigens, measurement of DNA synthesis and alamar 
BlueTM reduction. Example of proliferating antigens are proliferating cellular 
nuclear antigen (PCNA) which is essential for DNA synthesis and cyclins such 
as cyclin E which is expressed as cells move from G1 to S phase. DNA 
synthesis can be measured using 3H-thymidine or bromodeozyuridine (BrdU) 
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incorporation into nascently synthesized DNA. The latter is preferred as it is 
non-radioactive and can be easily detected with an antibody (Vackova et al, 
2003). This makes it suitable for immunohistochemistry. Alamar BlueTM 
reduction occurs when metabolites intermediates of the internal environment of 
proliferating cells (which is more reduced compared to non-proliferating cells). 
The reduction is then monitored spectrophotometrically. For our experiments, 
BrdU assay was chosen for its ease in detection via flow cytometry. 
Thymidine analogue, BrdU was added for last 6 h of culture as 
recommended. 1 x 106 cells/ml concentration was then fixed in 70% ethanol 
for 4 h prior to acid treatment of 15 min. Cells were then labeled with anti 
BrdU-FITC. Before flow analysis via Coulter imaging system, PI was added as 
a counter stain. 
 
3.18.4. Apoptosis assay 
One million cells/ml concentration was fixed in 4% paraformaldehyde 
for 20 min prior to 0.1% Triton X-100 permeabilization of 5 min on ice. Cells 
were then labeled with terminal deoxynucleotidyl transferase (TdT)-mediated 
dUTP nick-end-labeling with FITC-dUTP. Before flow analysis via Coulter 
imaging system, PI was added as a counter stain. 
 
3.19 Yeast two hybrid  
Protein-protein interactions are critical to biological processes of the 
cells. Y2H screening provides a fast and rapid method for identification on 
putative protein-protein interactions. Prior to the development of Y2H, 
Materials and Methods 
 56
identification of physical protein-protein interactions and their subsequent 
functional characterization are laborious and time consuming. The main 
advantage of Y2H is the ease of use of yeast as a genetic selection system. In 
addition, it relies on an assay performed in vivo and is thus not limited by 
artificial conditions of in vitro assays. Using a common protocol, a wide variety 
of protein-protein interaction can be detected (Vidal et al, 1999). The main 
disadvantage of the system is the presence of high percentage of false positives 
which have to be “weed” out after the initial screening. 
The Y2H system using 2 reporter yeast strains of different mating types. 
By itself, the yeast is unable to grow on dropout medias which do not contain 
Ade, His, Leu and Trp. Upon mating, if the 2 proteins (which are attached to 
respective activation and DNA-binding domain) in each strain interacts, the 
DNA-binding domain would bind to an Gal promoter fused with the reporter 
genes and the activation domain if in close proximity will activate transcription 
of the reporter gene which will allow the hybrids to grow on dropout media as 
depicted in figure 4. 
Yeast two hybrid screening was carried out using MATCHMAKER 
GAL4 Two-Hybrid system (Clontech). MOST-1 cDNA contain inherent NcoI 
restriction sites. Entire putative ORF of MOST-1 was generated using high-
fidelity Pfu DNA polymerase (Promega). The amplicon and pAS2-1 vector 
were then digested with the above restriction enzymes and ligated O/N at 4°C 
and transformed into E. coli competent cells, DH5α. In frame cloning of the bait 
construct was confirmed by sequencing prior to transformation into PJ69-2A 
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yeast cells using lithium acetate-based method. Fusion proteins from yeast 
lysates were checked with MOST-1 specific antibodies via Western blot. 
 
Figure 6: Schematic diagram on the mechanism of Y2H screen  
 
MATCHMAKER 2 pretransformed cDNA libraries (Clontech) of human 
bone marrow were screened via yeast mating. Mating was carried out by 
incubating 1 ml of the pretransformed library culture with the bait culture 
constructed above in YPDA/kan O/N at 30°C shaking at 30 rpm. Mating 
cultures were checked under phase-contrast microscope after 20 h for presence 
of zygotes and allowed to mate for a further 4 hours after which it is collected 
by centrifuging at 1000 g for 10 min. Mating flask was rinsed twice with 
YPDA/kan and the first pellet was resuspended before collecting cells by 
repeating centrifugation. Cell pellet was then resuspended in 10 ml of 





  DNA-binding domain (DNA-BD) 
• target to specific promoter sequences such as UAS 
 
Activation domain (AD) 
• facilitate assembly of transcription complex allowing for initiation 
of transcription 
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YPDA/kan. 100 µl of 1:10,000, 1: 1000, 1:100 and 1:10 dilution of the mating 
mixture were plated on SD/-leu, SD/-trp and SD/-leu/-trp plates to assay for 
mating efficiency while the remaining mating mixture were spread onto SD/-
Ade/-His/-Leu/-Trp (QDO) plates at 200 µl each. Plates were then incubated at 
30°C for 21 days. Colony appearance was checked every 3 days and 
subcultured on fresh QDO plates. Β-gal colony lift filter assay and direct 
colony PCR screening of positive clones for the presence of both the bait and 
the library were done using FAD and RADO (primers previously described in 
Sim et al, 2002) and MOST-1 specific primers. Sequencing of clones was done 
and analyzed using BLASTN and BLASTP algorithms. 
 
3.20 Transfection of mammalian cell lines 
Transfections was done with lipofectamine 2000 (Invitrogen) for 




The bait construct in yeast two hybrid experiments was subjected to 
Sal1 and Xho1 restriction enzyme reactions and cloned into pCMV-HA vector 
(Clontech) giving rise to HA-MOST1 while library interactors were cloned into 
pCMV-myc vector (Clontech) using restriction enzymes EcoR1 and Xho1. In 
frame cloning was confirmed via sequencing. 
A total of 1 ug of plasmid DNA were used in separate transfections 
using cytofectene (Biorad) according to manufacturer’s instruction. RPMI-
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1640 supplemented with 10% FCS and opti-MEM 1 (Gibco BRL). BHK cells 
at ~80% confluency were used for transfection and incubated in CO2 incubator 
for a period of 24 to 48 hours. Cells were washed trice with cold PBS prior to 
incubation on ice for 30 min with  mild lysis buffer containing 40 mM Tris (pH 
7.4), 300 mM NaCl, 20 mM EDTA (pH 8), 20% glycerol, 2% NP 40 and 
complete protease inhibitors (Roche). Cell debris was removed by 
centrifugation at 14,000 rpm for 15 min at 4°C. Lysates were then mixed in 
vitro and expressed proteins were co-immunoprecipitated overnight at 4°C with 
the respective antibodies and subsequently pulled down with protein A/G Plus 
agarose (Oncogene) for 2 hours before washing twice with PBS. SDS loading 
buffer was then added and the mixture was heated at 95°C for 5 min before 
loading onto SDS-PAGE gel and subjected to Western analysis. 
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4.1. Elucidation of MOST-1 full length sequence 
A novel EST was obtained using HPV E6 consensus primers on MOLT-
4 cDNA and named MOST-1 (MOLT-4 sequence tag 1). Sequence analysis of 
this EST showed no homology to any known gene in GenBank database 
(www.ncbi.nlm.nih.gov) or to HPV E6 gene. To obtain the full-length cDNA, 
RACE was performed on 2 libraries. MOLT-4 T-lymphoblastic leukemia 
cDNA of which MOST-1 was initially derived from and human fetal lung 
(MRC-5) cDNA. MRC-5 was chosen to demonstrate if MOST-1 could have 
any developmental function. Screening for this novel EST in the two RACE 
libraries authenticated its presence in both (Fig 7A). Isolation of the full-length 
cDNA sequence corresponding to this EST from which specific primer pairs 
TF1, TR1, TF2, TR2 were designed for use in RACE experiments. All DNA 
bands obtained were excised and sequenced, of which products of ~1.6 kb and 
~1.2 kb were generated via 3′ and 5′ MOLT-4 RACE, respectively. (Figure 7B) 
The MRC-5 library yielded bands of ~1.6kb and ~0.5kb from 3′ and 5′ RACE 
reactions, respectively. See Figure 7C. All other bands were either truncated 
sequences or self-priming products of primers. Cycle sequencing of the 
overlapping 3′ and 5′ RACE fragments revealed composite cDNA sequences of 
2786 bp and 2054 bp in MOLT-4 and fetal lung, respectively (Fig. 8). The 
latter cDNA sequence in fetal lung was identical to nt 664-2705 of its MOLT-4 
counterpart. The resultant cDNA sequence of 2786 bp was found to contain a 
continuous ORF of 297 bp with an in-frame nonsense codon 168 bp upstream 
of the putative start codon. The first methionine codon lies in an extremely 
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favorable context for translation initiation, i.e. GGCACCATGG, which 
conforms exactly to the ideal sequence for a eukaryotic translation start site 
(Kozak, 1991). Northern analysis results in a high background which may be 
due to the Alu repeat present in MOST-1. Hence screening of normal tissue 


























Figure 7A: RACE screen of MRC-5 (human fetal lung) and MOLT-4 (T-lymphoblastic leukemia) 
cDNA library. MOST-1 EST was found in both MOLT-4 and MRC-5 RACE cDNA library. Screening was 


























Figure 7B: RACE products of MOLT-4 cDNA RACE library. As MOST-1 cDNA was present in low 
amounts, nested RACE experiments was done. 3’ RACE showed a ~1.6 kb fragment, lower bands were 
truncated versions. 5’ RACE obtained a 1.3 kb fragment. Self priming controls were done to eliminate non-
specific bands in the reaction. Positive controls were done with G3DPH primers provided to verify RACE 
library integrity. 


























Figure 7C: RACE products of MRC-5 cDNA RACE library. As MOST-1 cDNA was present in low 
amounts, nested RACE experiments was done. 3’ RACE  obtained a 0.5 kb fragment all other fragments were 
truncated  versions or self priming products. 5’ RACE obtained a ~ 1.6 kb fragment. Self priming controls 
were done to eliminate non-specific bands in the reaction. 
























Figure 8: Schematic diagram of MOST-1 full length cDNA upon sequence analysis. There is a region of 
overlap of the 3’ and 5’ RACE fragments as indicated in both RACE libraries. Red box showing Alu repeat 
region. Alu repeat has been implicated for gene amplification and jumping phenomenon. Blue box illustrates 
Kozak sequence location comprising of the first methionine for translation of ORF. Ideal Kozak sequence in 
MOST-1 indicates high translation efficiency. Green box (R) represents AUUUA RNA degradation motifs. 
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Figure 9: Nucleotide sequence of full length MOST-1 sequence from MOLT-4 RACE. Putative ORF sequence in green; 
Highlighted region in yellow is sequence used for synthetic peptide generation; Kozak sequence in red; RNA destabilizing 




4.2. Bioinformatics analysis of MOST-1 putative ORF 
A computational translation of the methionine at the Kozak 
sequence predicted a potential ORF of 99 amino acids (illustrated in 
Figure 9 as green) forming a basic, hydrophilic protein (grand average 
of hydrophobicity of –0.417) of 11,219 Da. This putative protein had an 
isoelectric point of 8.59, and was classified as unstable in nature with an 
instability index computed to be 76.92 using ProtParam tool 
(www.expasy.ch). In this program, instability index above 40 indicated 
an unstable protein based on previous statistical analysis of 12 unstable 
and 32 stable proteins (Guruprasad et al, 1990).  No notable amino acid 
sequence motifs were evident but three ATTTA mRNA destabilizing 
signals (Shaw and Kamen, 1986) were present in the 3′ untranslated 
region (UTR) of the gene. MOST-1 cDNA sequence was deposited in 
GenBank under accession number AF220264 with a symbol C8orf17 by 
the HUGO Nomenclature Committee. 
 
Analysis of MOST-1 putative ORF 
Figure 10 shows glycine at aa2 was predicted to be a N-
myristoylation site while threonine at aa19 and 29 were predicted to be 
casein kinase II phosphorylation sites and serine at aa69 and 91 were 
predicted to be protein kinase C phosphorylation sites. Serine at aa91 is 
also predicted to be a site for O-glycosylation while lysine80 is a 
potential sumoylation site. Protein predict program predicted MOST-1 
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to be non-globular in nature which correlates with a predicted secondary 
structure with predominant extended sheet structure from aa7-11, aa34-
56, aa60-64, aa67-71 and aa80-81. At the same time, ProtParam predicts 
MOST-1 to be an unstable protein.  
 
4.3. MOST-1 genomic structure analysis 
To search for introns, concurrent PCR reactions were carried out 
with primer pairs flanking approximately 200bp products with 
overlapping sequences. The PCR products were then excised and the 
sequences of PCR products amplified from cDNA and genomic 
templates respectively using identical primer pairs were compared but 
showed no differences. Primer pairs indicated in Figure 11 with 
templates cDNA and genomic respectively. Most of the primer pairs 
gave identical size fragments with the exception of those primers in the 
5’UTR of MOST-1 when using MRC-5 as a template due to the shorter 
gene fragment as found by RACE. MOST-1 is also present in lower 
amounts in MRC-5 cDNA preparations resulting in low intensity 
products which are apparent only upon high exposure time to UV during 
photography. Since the products were the same size, it indicates that 
MOST-1 do not contain introns and hence intronless.  
Subjecting the MOST-1 cDNA sequence to computational 
analysis by exon-intron search engines such as Grail also arrived at the 




FIGURE 10: Summary of computational analysis of MOST-1 putative ORF. 5 motifs were elucidated using 
various bioinformatics analysis indicated in methods. N-myristoylation is a protein modification which promotes 
binding of protein to membrane. CKII phosphorylates at S/T and tend to be elevated in neoplastic and proliferating 
tissues. Sumoylation is an enzymatic process analogous to ubiquitination and plays an important role in intracellular 
protein localization. O glycosylation is found mainly on membrane proteins. Protparam predicts putative ORF to be 
highly unstable, with a predicted size of 11.2kDa. 
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FIGURE 11B: Intron/Exon Mapping of MRC-5 cDNA and gDNA 
 
 







Figure 11: Genomic Structure analysis of MOST-1. Mapping of 
intron/exon junction was done using primers pairs indicated in Table 6. 
PCR of paired cDNA and gDNA shows no difference in cDNA and 
gDNA PCR products from predicted size suggesting MOST-1 to be 
intronless. 
 
   1        2       3      4       5      6        7      8 
   1        2       3       4       5        6       7       8 
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Table 7: Primer Pairs and product size used in mapping for Figure 11 


















































4.4. Expression Profile of MOST-1 
Cell Line Screening shows that MOST-1 is ubiquitously expressed in 
cancer cell lines but differentially expressed in normal human tissues. 
RT-PCR with MOST-1 specific primers TF5 and TR4.2 yielded 
expected 440-bp target fragments of detectable but varying intensities 
from cDNAs of 19 human cancer cell lines and two normal cell lines 
tested. However, out of 16 normal human adult tissues tested, MOST-1 
RT-PCR products were detectable in only 9 tissues (heart, kidney, liver, 
pancreas, small intestine, ovary, testis, prostate, thymus), but not in 
others (brain, lung, skeletal muscle, colon, placenta, spleen, peripheral 
blood leukocyte). The G3PDH and/or HUEL housekeeping genes 
served as cDNA quality controls, and were successfully amplified from 
the tested human cell lines and adult tissues. To authenticate the PCR 
reaction, human total cDNA with or without G3DPH primers were 
carried out in the positive and negative controls respectively (Figure 
12B top panel, lanes 17 and 18).  Figure 12 illustrated the reamplified 
products, while Table 7 illustrated the initial products band intensity 
reading followed by normalizing with G3DPH product band intensity. 
See Appendix 4 for densitometric readings. Both reactions were stopped 




Table 8: Comparative MOST-1 Expression in Human Tissues, Normal and  
     Cancer Cell Lines 
Normal tissues MOST-1 : 
G3DPH ratioa Cell lines 
MOST-1 :  
G3DPH ratioa 
Pancreas 0.61 MRC-5 fetal lung cells 1.35 
Prostate 0.57 Breast myoepithelial cells 1.15 
Ovary 0.55 MDA-MB-231 breast adenocarcinoma 2.11 
Testis 0.33 
Hs578T breast ductal 
carcinoma 1.14 
Liver 0.33 MCF7 breast adenocarcinoma 1.13 
Heart 0.31 
ZR-75-1 breast ductal 
carcinoma 0.44 
Kidney 0.31 PC-3 prostate adenocarinoma 1.20 
Thymus 0.28 DU145 prostate carcinoma 1.13 
Small intestine 0.26 CaSki cervical carcinoma 1.18 
Lung* 0.17 HeLa cervical carcinoma 1.06 
Peripheral 
leukocyte* 0.17 SiHa cervical carcinoma 0.90 













  KATO III gastric carcinoma 0.76 
  U-937 histolytic lymphoma  1.59 







aAll cDNA samples were subjected to PCR with MOST-1 and G3DPH primers, and the individual 
ratios of the densitometric readings of their amplified products were calculated. 
*Denotes samples for which no MOST-1 amplified products were observed by agarose gel 
electrophoresis. 

































































Figure 12: MOST-1 expression profile. Figure 12A shows MOST-1 found in all cancer cell lines tested, 
one fetal (lung) cell line and one normal epithelial cell line. This suggest a role for MOST-1 in cancer 
progression. Figure 12B shows MOST-1  found to be differentially expressed in normal tissues suggesting a 









4.5. Genomic Localization of MOST-1 
Fluorescent in situ hybridization (FISH) Map MOST-1 gene to  
chromosome 8q24.2 with a detection efficiency of ~50% was attained 
with the FISH probe, i.e. out of 100 mitotic figures checked, 50 
displayed hybridization signals on one pair of homologous 
chromosomes. Using DAPI banding to identify the specific 
chromosome, the assignment between the signal from the probe and the 
long arm of chromosome 8 was obtained. Based on a summary of ten 
photographs, MOST-1 was localized to a more precise position at 
chromosome 8q24.2 (Fig. 13), and no other loci were detected with the 
probe. The MOST-1 sequence was also mapped by UniGene 
computational analysis to chromosome 8q24.3. 
  
           A                                         B                                        C  
      
Figure 13: Chromosomal Localization of MOST-1. FISH analysis of MOST-1 with specific probe shows MOST-1 localization 
to 8q24.2, a region reported to be amplified in a number of cancers especially breast and prostate cancers. A: Staining of 
chromosome with MOST-1 specific probe on both alleles. B: DAPI staining of chromosomes of same metaphase spread. C: 




4.6. Breast Biopsies Screening 
Semi-quantitative PCR analysis shows that MOST-1 is 
overexpressed in a Subset of Breast Cancers 
MOST-1 expression in paired breast tissue biopsies was 
compared by first normalizing densitometric readings of MOST-1 with 
G3PDH RT-PCR products, and then calculating the ratios between 
corresponding tumor and adjacent normal tissues (T:N). Out of 27 
paired biopsy samples tested, relative T:N expression of MOST-1 was 
increased in 11 pairs (41%), unchanged in 4 (15%), and decreased in 
another 12 (44%).  Real-time RT-PCR performed on 12 randomly 
selected pairs of tumor and normal tissues revealed MOST-1 expression 
data in six grade 1 and 2 cancers and six grade 3 cancers consistent with 
semi-quantitative RT-PCR results Graph 1. The T:N ratio of MOST-1 
expression demonstrated a correlation with breast cancer grade, i.e. 
mean ratios for grade 1 and 2 versus grade 3 were 0.84 versus 1.69 by 
semi-quantitative RT-PCR, and 1.41 versus 2.92 by real-time RT-PCR. 
Though there is a relative 2 times increase in ratio for both methods, the 
differences between the means for grade 3 versus grade 1 and 2 cancers 



































Graph 1:  T/N Ratio of MOST-1 gene expression in tumor biopsies compared to normal showed increased MOST-1 expression
in tumor biopsies. Semi-quantitative analysis of normalized densitometric reading of PCR products in log phase are expressed as
open diamonds while real time cT values are indicated in green triangles. Average of semi-quantitative analysis of Grades 1 & 2 and
3 biopsies are 0.837 and 1.687 (indicated by blue lines) respectively; demonstrating a 2 fold increase in MOST-1 expression. Real
time analysis of 12 randomly picked samples in the pool showed a similar 2 fold increase in MOST-1 expression levels with mean
T/N ratio of 1.415 and 2.91 respectively for Grades 1 & 2 compared to Grade 3 biopsies (indicated by black lines).
T/N = 1
Grade 1 & 2 Grade 3
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4.7. Prostate Biopsies Screening 
Real time PCR analysis MOST-1 DNA Copy Levels are increased in 
Prostatic Neoplasia 
Owing to the relatively low incidence of prostate cancers in Singapore, 
a statistically sufficient number of paired biopsies of prostatic cancer 
and adjacent normal tissues were not readily available. Hence, we 
resorted to analyze DNAs from a total of 61 histological assessed, 
archival prostate biopsy sections, i.e. 15 normal prostates, 21 benign 
prostatic hyperplasia and 25 prostatic carcinomas. All DNA samples 
were subjected to real-time PCR experiments to derive each individual 
∆CT value, i.e. the difference between the threshold cycles for MOST-1 
and G3PDH gene detection. The formula 2-∆CT was employed for 
quantitation of the DNA levels of MOST-1. By comparing the mean 
∆CT value of normal samples (as the benchmark reference) with those 
of prostatic neoplasia, relative MOST-1 DNA levels were increased in 
cancer tissue compared to hyperplasia and normal tissues as shown in 
Graph 2A. By subdivision of cancer tissue to low, intermediate and high 
grade carcinoma based on Gleason scores which correspond to 3-5, 6-7 
and 8-9 respectively. MOST-1 DNA copy number was shown to 
increase by 1.4-fold in hyperplasia, by 9.9, 7.5 and 4.2-fold in high, 
intermediate and low grade carcinomas. Multiple comparisons between 
the mean for normal tissues against the individual means for neoplastic 
tissues indicated that the differences for hyperplasia or low grade 
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cancers were statistically significant (p=0.014 and p=0.002, 
respectively), and for intermediate or high grade cancers were highly 




Graph 2: Relative real time quantification of MOST-1 in prostate biopsies.
Graph 2A: Threshold cycles of MOST-1 normalized with G3DPH showing normalized relative DNA copy number in 3 groups
of tissues. Results indicate that there is a general trend for increasing DNA copy number in carcinoma compared to normal but not so
between hyperplasia and normal.























































Graph 2B: Relative DNA copy number in prostate cancer biopsies expressed against normal tissue. DNA fold number from
above was compared to mean of normal sample as benchmark to obtain relative DNA copy number. In addition, carcinoma samples
were subdivided into low (Gleason score 3-5), intermediate (Gleason score 6-7), and high (Gleason score 8-9) grade carcinoma.





4.8. Polyclonal antibody generation and verification 
4.8.1. Dot Blot analysis 
To characterize MOST-1 protein, polyclonal antibody was raised against 
synthetic peptide TGPEQSDICHTGSEAR. Peptide sequence was 
subjected to BLASTp analysis against known protein sequence in 
GenBank prior to synthesis. Criteria for selection of peptide sequence 
include a hydrophilic and antigenic region in the putative ORF of 
MOST-1 protein after analysis with Plot Structure (Figure 14). 3 rabbits 
were immunized with synthetic peptide resulting in 3 polyclonal anti-
sera. 2 of the anti-sera immuno-dot blot screening showed hyperimmune 
antibodies reacting strongly to conjugated and unconjugated peptide, 
whereas their respective preimmune sera were nonreactive (Figure 15). 
Polyclonal antibody #235 was then selected for affinity purification 
using peptide-bound column for use as a probe in Western and confocal 
analysis.  
 
4.8.2. Polyclonal antibody recognizes aggregated form of MOST-1 
During the characterization of affinity purified polyclonal antibody with 
Western analysis on MOLT-4 lysate showed that it only recognizes 
aggregated form of MOST-1 (Figure 16A). This prompted the 
expression of recombinant MOST-1 in TNT experiments which also 
illustrate the polyclonal antibody recognizing the high molecular weight 
product despite a ladder of different MOST-1 isoforms ranging from 
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15kDa to > 100kDa. This finding suggests the propensity of MOST-1 to 
self-aggregate in solution. Figure 16B shows differential treatment to 
TNT products illustrating that the aggregated MOST-1 is SDS soluble 
but upon thermal stress, the aggregated MOST-1 becomes SDS-
insoluble. These data is in line with the computational analysis where 
MOST-1 is predicted to be unstable as a monomer and insoluble. 
Secondary structure analysis with PredictProtein (www.expasy.ch) 
shows a stretch of extended βsheets from aa34 to 70 suggesting the 




Figure 14: MOST-1 ORF analysis using PlotStructure. Synthetic peptide region was selected based on its 
hydrophilic nature and antigenicity as indicated in analysis above.  
 




















Figure 15: Dot-Blot of 3 rabbit sera after immunization with conjugated 
peptide. Pre and Post immune sera reactivity to peptide were compared with 
#235 showing the most-obvious increase to unconjugated peptide suggesting a 
specific antibody reaction. U: unconjugated peptide dotted on membrane; C: 
Conjugated peptide dotted on membrane.* #235 showing darkest response to 
Dot Blot for unconjugated peptide. 
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Figure 16A: Polyclonal antibody recognition of high molecular weight 
MOST-1 protein in TNT experiments. Western analysis using affinity 
purified antibody showed specific recognition of high molecular weight 































Figure 16B: Differential Treatment of TNT expressed recombinant MOST-1 protein in non-reducing 
conditions. Western analysis with antibody shows specific recognition of high molecular weight species which is 




4.9. Subcellular localization of MOST-1  
Figure 17 shows the cytoplasmic stippling of MOST-1 (stained green) and 
with respect to the nucleus (stained red with PI) in 4 different cell lines, 
coinciding with previous observation the MOST-1 is most probably in 
aggregates in cells. There is a visually higher MOST-1 expression level in 
corresponding cancer cell lines as compared to their normal-like 
counterparts suggesting that overexpression of MOST-1 in cancer cells may 
be a cause of its aggregation.  
Western Blot Analysis showed MOST-1 is found predominantly in the 
microsomal fractions as shown in Figure 18 shows the presence of 2 
different size endogenous proteins in MOLT-4 cell lysate with the 
predominant 100kDa fragment and a lower 70kDa protein present in the 





Figure 17: Confocal Microscopy of MOST-1 in various cell lines of breast 
and prostate origin. MOST-1 appears in cytoplasmic stippling with focal 
points in dividing cells. There is also a visual increase of MOST-1 in MCF7 
breast carcinoma compared to normal breast epithelial cells. 
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Figure 18: MOST-1 cellular localization studies in PP5 and MOLT-4 cell lines. MOST-1 
shows different localization mainly in the nucleus and both microsomal and nuclear fractions 
respectively. There is also the presence of 2 species, the 70 kDa protein and high molecular 
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4.10. Cell Synchronization Studies 
As confocal microscopy showed localization of MOST-1 to a region 
during cell division, cell synchronization studies were design to 
investigate the association of MOST-1 to cell cycle. Mimosine has been 
shown to arrest cells in G1 stage prior to DNA synthesis. Removal of 
mimosine from media will result in reversible cell cycle progression. To 
type the population of cells undergoing cell division, PI staining of fixed 
cells was done. In brief, G2 cells will contain 2 times as much G1 PI due 
to increase DNA in cells and S phase cells will have an intermediate 
value between the two. In addition, confocal microscopy was done in 
parallel to visualize MOST-1 expression. As shown in figure 19, 
MOST-1 has no clear relation with DNA content of the cells.  Confocal 
microscopy at time intervals however suggest MOST-1 expression is 
reduced for a ‘window’ but this timing differs between cancer cells and 
normal cells as shown in Table 8. Cells appear to be staining more 
intensely as compared to Figure 17 suggesting an increase in MOST-1 
expression level. Closer inspection of the cells shows MOST-1 in 




Figure 19: Cell Synchronization Experiments 
 










G1 : 54 % 
S : 7.8 % 
G2 : 10.05 % 
G1 : 64.95 % 
S : 6.92 % 
G2 : 7.08 % 
G1 : 44.52 % 
S : 9.26% 
G2 : 7.28 % 









G1 : 38.56 % 
S : 5.21% 
G2 : 6.33 % 
G1 : 54.77 % 
S : 7.44 % 
G2 : 8.27 % 
G1 : 44.49 % 
S : 6.83 % 









G1 : 43.29 % 
S : 7.83 % 
G2 : 8.80 % 
G1 : 46.08 % 
S : 9.75 % 
G2 : 8.40 % 
G1 : 29.77 % 
S : 9.48 % 
G2 : 7.31 % 
  








G1 : 61.49 % 
S : 10.36 % 
G2 : 11.02 % 
G1 : 69.87 % 
S : 10.94 % 
G2 : 10.04 % 
G1 : 62.78 % 
S : 10.06 % 









G1 : 57.16 % 
S : 15.68 % 
G2 : 10.47 % 
G1 : 67.81 % 
S : 12.70 % 
G2 : 10.01 % 
G1 : 65.51 % 
S : 15.00 % 










G1 : 58.90 % 
S : 18.98 % 
G2 : 11.53 % 
G1 : 29.11 % 
S : 15.93 % 
G2 : 27.89 % 
G1 : 23.26 % 
S : 10.78 % 
G2 : 26.54 % 
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TABLE 9: Summary of cell synchronization comparison of MCF7 and  
                   normal mammary cell lines vs. MOST-1 expression levels. 
  
Time (h) Normal Mammary Cells Cancer Breast MCF7 Cells 
 Expression Levela Localizationb Expression Levela Localizationb 
0 - - +++ Punctate C+ N 
2 ++ C Stippling + N  +++ Punctate C+ N 
4 ++ C Stippling + N  +++ Punctate C+ N 
6 +++ Punctate C+ N ++ Punctate C+ N 
8 ++ C Stippling + N  + C Stippling 
10 + C Stippling + C Stippling 
12 + C Stippling - - 
36 ++ C Stippling + N  + Punctate C+ N 
48 - - ++ Punctate C+ N 
 
aExpression levels of MOST-1  
-: negligible; +: faint; ++: visible expression; +++: high expression. 
bLocalization of MOST-1 
punctuate: large round vesicular pattern; stippling: small round vesicular pattern 
C: cytoplasmic; N: nuclear 
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4.11. Yeast two hybrid  
A total of 36 clones were obtained and these were subjected to 
verification via colony lift assays and PCR screening shown in Figure 
20. Clones which contain both plasmids and positive for colony lift 
assays were selected and sequenced. Only clones which are in frame 
with the tag and expressed a known protein were selected. Of these, 
overlapping clones were aligned and 7 putative interactors were 
identified. The interactors were namely creatine kinase(overlapping 
clones coincide between nt1192-1555, end part of ORF), ferritin 
(overlapping clones coincide between nt4-219, encompassing the start 
part of ORF), peripheral benzodiazepine receptor (interaction region 
between nt156-373, within the ORF), immunoglobulin C(mu) and 
C(delta) heavy chain genes (interaction region of nt15191-15331, part of 
ORF), SNC73 protein (interaction region of nt1047-1416, within ORF), 
Gardner feline sarcoma v-FGR oncogene (interaction region of nt1327-
1547, within ORF) and telethonin (interaction region of nt336-555, 
within ORF).  The interactors amino acid sequence were aligned (after 
elimination of vector and tag sequences) for elucidation of potential 
pattern formation. No obvious pattern could be observe but there seem 
to be a C – X(>40) – P – X(4-19) – P consensus as shown in figure 21. 







Co-immunoprecipitation was carried out with 3 of the 8 interactors, namely 
human immunoglobulin C (mu) and C (delta) heavy chain, peripheral-type 
benzodiazepine receptor and ferritin light chain. Pull downs with anti-HA and 
anti-myc separately were done and detection with tagged antibodies were used 
to confirm the above 3 interactions. Figure 22A showed the single expression 
of interactors expression prior to co-immunoprecipitation while figure 22B 
showed the respective interactors with MOST-1 after pull down with anti-HA 
and detected with anti-myc and vice versa for figure 22C.  
 
 
Figure 20: Screening of Y2H interactors. Colony lift assay shows positive clones as dark blue colonies after Buffer Z 
addition; 25 positive clones were selected out of 36 interactors picked. PCR screen showing presence of both AD and BD 
plasmid in hybrids was done in which 19 positive clones out of 36 were selected. Overlapping 19 positive clones from the 2 









P                1 -----------------CGS-------PG-PLHWAAGPELGMAPHLLWCPTNGLG----- 
SNC73            1 ----GKSAVQGPPERDLCGCYSVSSVLPGCAEPWNHGKTFTCTAAYPESKTPLTATPLKI 
Ig               1 -------------------------------QEERETKTPECPSHTQPLGVYLLT----- 
Ferritin         1 ------------RGSVSCFN--------SVWTEQIRGLXSSLRPPSDFLSACNLR----- 
Extracellular    1 ---------------LACKIADFGLARLIKDDEYNPCQGSKFPIKWTAPEAALFG----- 
CK               1 RRHDPRPEVGACPPATDCWN-------PASGRAWPTRVLLPHSSPRPLSQSPTWG----- 
Telethonin       1 ----------PPSSFRSCWR--------W-RQPWVASVWTARRWLRSQSSCPLWCLS--- 
consensus        1                  .               .                  . .      
 
 
P               31 ------LGGSPAGQWGGGSHYRG---LVPG---EPAGRP---------------PALPLP 
SNC73           57 RKHIPARGPPAAAAVGGAGPERAGDADVPGTRLQPQGRAGSLAAGVTGAAPREVPDLGIP 
Ig              25 --------PAVQDLWLRDKATFT---CFRGGQ-RPEGCS---------------PDLG-- 
Ferritin        36 -----DHLLGHLLLLGPASTVFVVSSFLPTNHELPDSVR-------------IIPTD--- 
Extracellular   41 ------RFTIKSDVWSFGILLTEL--ITKGRIPYPGMNK---------------REV--- 
CK              49 -----LSPPFSEFQFQPEFQPMGSILWILANEISPWQGP------------LLFPELHPN 
Telethonin      39 ------ASPVHFVAPCPAPCPRKHREAERDCDLGSRCAR---------------PG---- 
consensus       61         .     .  .         . .    .                   ...    
 
 
P               64 -GLAGLHDHT----------------- 
SNC73          117 AGAQPGHHHLRCDQHTARGSRGLEEGG 
Ig                 --------------------------- 
Ferritin           --------------------------- 
Extracellular      --------------------------- 
CK              92 QEL------------------------ 
Telethonin         --------------------------- 
consensus      121                             
 
 
Figure 21: Alignment of Y2H interactors for consensus sequence search. Positive in frame interactors were 
aligned using Clustalw and consensus sequence was searched to identify possible motif for interaction with 




Table 10: Putative interactors – their localization and function. 
Putative Interactors Cellular Location Reference 
Creatine Kinase 








Discrete pools in cytosol 
or extracellular 




Mitochondria Chaki et al, 1999 
Immunogluobulin (mu and 
delta) heavy chain regions 
 
Endoplasmic reticulum 
before secreted  
Mielenz et al, 2003 




Membrane bound Baker et al, 1998 
Telethonin  (titin-cap) 
 
Z-line of sarcoma Zou et al, 2003 
SNC73 protein 
 





























































































4.12. Overexpression and RNA interference studies  
RT-PCR was chosen for detection of MOST-1 expression as analysis of 
cDNA showed 3 RNA degradation signals suggesting a control at 
transcript level rather than protein level. After mRNA extraction was 
done, RT-PCR was carried in the log phase of amplification as 
previously determined for biopsies studies. Figure 23 shows the RT-
PCR results of MOST-1 after treatment in the various cells. RNAi was 
more pronounced in normal cell lines but there is a marked knock down 
of MOST-1 endogenous transcript levels in the cancer cell lines. 
Overexpression is not very overt despite the use of vectors with CMV 
promoters. Since overexpression was done with transient transfection of 
MOST-1, the low expression level could be due to the control of 
MOST-1 expression in cells as cotransfection of luciferase showed 
positive transfection. Since RNAi experiments worked, cell proliferation 
was measured using BrdU assay while apoptosis was quantitate using 
TUNEL assay on cells transfected with RNAi. Results are then tabulated 
in Graph 3.  
  
Figure 23: RT-PCR analysis of various cell lines subjected to overexpression and RNAi experiments. Overexpression 
(lane 4) for all was not overt when compared to vector control and untreated samples (lanes 1 and 2) for densitometric 
analysis. RNAi treatment (lane 5) was more pronounced compared to scrambled sequence and untreated samples (lanes 1 
and 3) suggesting specific knock down due to duplex RNA used. 
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Lane 1: Untreated 
Lane 2: Vector control 
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Graph 3: MOST-1 RNAi effect on cell proliferation and apoptosis
Graph 3A: Mean cell proliferation of RNAi treated cells by BrdU assay. Knock down of RNAi
showed an increase in prostate (PE) and mammary (ME) epithelial cells and a decrease for prostate
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Graph 3B: Mean cell apoptosis of RNAi treated cells measured using TUNEL assay. Knock down
of RNAi showed an increase in BHK, prostate epithelial and carcinoma cells and a decrease for














CHAPTER 5. DISCUSSION 
Strategy and Isolation of MOST-1 
Initial study by Couturier et al showed that DNA of HPV are found integrated in 
the cell genome in most invasive genital carcinomas as compared to intraepithelial 
neoplasia where HPV DNA is detected most commonly as episomal molecules. 
Subsequently, it was found that greater than 99% of all cervical tumors contain HPV 
DNA and studies have shown that this integration is non random and occurs at loci 
containing human common fragile sites (CFS). CFSs are described as specific loci 
that form gaps or breaks in metaphase chromosomes from cells that have been 
challenged with chemicals that induce replicative stress. There are 89 CFSs in the 
human genome and CFSs are present in all primates, lower mammals and possibly 
yeast. The mechanism of CFSs fragility is currently under investigation (Ferber MJ et 
al, 2003). Feber et al, 2003 reported that 30% of all HPV 18 integration occurred 
within 8q24 near the c-myc proto-oncogene. The c-myc locus is coincidently next to 
the chromosomal location of MOST-1, 8q24.2. They have also shown that multiple 
genes are interrupted by the integration many of which include tumor suppressors, 
proto-oncogenes and genes maintaining DNA integrity. Integration of HPV genome 
frequently results in the functional elimination of the viral repressor and remodeling 
of the E6/E7 promoter, which then lead to the continued expression of E6 and E7 
oncoproteins. E6 and E7 oncoproteins of HPV have been shown to direct cell cycle 
progression and play a major role in HPV-induced carcinogenesis by interfering with 
the host cell regulatory proteins (Munger et al, 1989). Overexpression of E6 and E7 is 
insufficient to immortalize primary cells, thus additional alterations such as activating 
ras mutations are required to transform them (Ferber et al, 2003). In addition, E6 and 
E7 interact with the tumor suppressors p53 and pRB and thus provide a mechanism 
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for the cells to accumulate genomic damage (Ferber MJ et al, 2003). Loss of tumor 
suppressor function, acquisition of unrestrained replicative ability and eventual loss of 
genomic stability are hallmarks of cancer. Recent reports illustrate that reduction of 
E6 and E7 by RNAi, in cell line (HeLa) transformed with HPV18, induces 
senescence. This correlates with previous studies that E6 and E7 immortalize cells. 
The authors showing that RNAi of E6 and E7 inhibited cellular DNA synthesis and 
induced morphological and biochemical changes characteristic of cellular senescence 
further lends support to the above (Hall et al, 2003). This study attempt to isolate 
genes using HPV primers which have a role in cell cycle from MOLT 4. MOLT-4 is a 
cancer cell line which was not transformed with HPV and hence do not have HPV 
genome integration thus reducing the background amplification of HPV genes with 
the consensus primers.  The primers derived from HPV 18 and HPV 11 E6 genes are 
found to target a sequence in the middle of the ORF of a novel EST, MOST-1. Should 
this be the site of integration, HPV integration would disrupt the gene and prevent its 
function and thus confirming the studies cited. Similarly, it could also mean that 
MOST-1 might function in cell cycle or its regulation. Characterization of this gene 
was undertaken in the hope of elucidating its function. 
 
MOST-1 Gene 
The MOST-1 gene was found to be intronless. New identification of 
intronless genes in vertebrates makes exceptions to the rules that all eukaryote 
mRNA undergoes splicing. Indeed, this property have been predicted to occur 
in ~5% of the genes (Gentles AJ et al, 1999). Graph 4 shows the prevalence of 
intronless genes in humans to be approximately more than 10% of known 
genes in GenBank currently (4000 of the predicted 30, 000 genes). Of the 4000 
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genes found, 8% of kinases, 44% of helix-loop-helix containing proteins and 
35% of cell surface receptors. These genes are commonly found in cell cycle 
regulation. Histones, cytokines and G-proteins are the main families of 
intronless genes. Histones are small proteins with an average size of 130 amino 
acids and have a high degree of protein sequence conservation. G-proteins are 
thought to be either derived from a single intronless common progenitor or 
introns are subsequently lost. Human G-protein-coupled receptors, majority 
related to brain function, function to mediate ligand-induced signaling (Gentles 
et al, 1999). Some other examples of functional intronless genes are CDR1 
(cerebella-disease-related antigen), SOX3, α-interferon β-adrenergic receptor 
and JUN proto-oncogene. Many of which have been identified to be  also 
related to brain function (Redolfi et al, 1998). 
It has been suggested that intronless genes not requiring post-
transcriptional splicing, might be more efficiently transcribed with greater 
abundance and have a higher rate of protein expression. This in turn results in 
genes which are not liable to differential and aberrant splicing and thus 
resulting in higher transcriptional fidelity (Gentles AJ et al, 1999). The origin 
or evolution of intronless gene in mammals is still under debate. There are 
however several suggestions such as having a single intronless common 
progenitor relatively recent in evolution with insufficient time to allow gain of 
introns as in the case of dopamine receptors, retroviruses transforming multi-
exon genes when they integrate into host genome nearby as in the case of src or 
via transposable elements with the latter two mechanism having a common 
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preference towards GC-rich sequences (Gentle et al, 1999). All this evidence 
support MOST-1 to be a functional gene despite its intronless nature. 
 
Graph 4: Number of intronless genes compared across genomes 
 
Adapted from http://sege.ntu.edu.sg/wester/intronless/statistics.htm 
 
Structural analysis of MOST-1 cDNA suggest an unstable transcript, with a 
strong consensus sequence at the putative methionine start codon (Kozak, 1991) of a 
potential ORF encoding a relatively small protein. Present within the 3´ UTR of 
MOST-1, three AUUUA motifs, which is a highly conserved sequence repeated three 
or more times in RNAs encoding many short-lived cytokines and proto-oncogenes 
(Akashi et al., 1994). Stability of mRNA is determine by the number of AUUUA 
motifs, which is a highly conserved sequence of AU rich region of ~50bp (called 
ARE) and is repeated three or more times in the 3’ untranslated region (3’ UTR) of 
short-lived cytokines and oncogenes. These motifs confer instability. The rank order 
of stability was 1x ATTTA = 2x ATTTA (no RNA decay at 4h) > 3x ATTTA = 5x 
ATTTA (t1/2 is 4h) > 7x ATTTA (t1/2 is 2h) (Akashi et al, 1994). ARE triggers 
destabilization by ARE-binding protein attaching to AUUUA motif and cause 
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deadenylation with poly (A) ribonucleus followed by decay with endonucleases. 
Deadenylation causes loss of poly(A)-binding protein which stabilizes the 3’ region. 
General model of mRNA stability is conferred by inhibiting function of destabilizing 
sequences (Lewin, 1997). The structural analysis of MOST-1 indicates that although 
this gene is efficiently translated, its expression seems to be controlled at the mRNA 
level. There is also an Alu repeat at the 3’ end of ORF of MOST-1. Alu repeats are 
part of the transposable elements that are found in large number of human protein-
coding genes (Nekrutenko A et al, 2001). Alu elements are a family of short 
interspersed elements which contain eight putative donor sites and three acceptor sites 
and with ~1.4 million Alu elements interspersed throughout the genome (out of which 
1.3% occurs in human coding regions), this provides numerous possibilities of 
formation of alternative transcripts. At the same time, it has been found that Alu 
insertion occurs once in every 200 human births suggesting that Alu elements could 
have contributed significantly to divergence between primates and other mammals 
because Alu elements are exclusively in primates (Nekrutenko A et al, 2001).  Alu 
elements are scattered by ‘retrotransposition’ which involved three independent steps: 
transcription of the Alu repetitive element, reverse transcription of Alu RNA and 
integration of Alu cDNA (Szmulewicz MN et al, 1998). The significance of Alu is 
still under debate but in all studies, it is agreed that Alu repeats remain one of the 
major driving force of evolution. In addition, there is a suggestion that variation of 
retroelement distribution in the human genome is associated with age and proximity 
to genes being the oldest Alu elements preferentially found in regions of lower GC. 
The presence of an Alu repeat at the 3’ end of the gene together with MOST-1 
intronless property suggest an evolutionary conservation which in turn suggest the 
possibility of MOST-1 being involved in fundamental processes such as cell survival. 
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The generally low abundance of MOST-1 mRNA in normal adult tissues 
was reflected by the necessity for reamplification during screening for tissue 
expression of MOST-1, and by the inability to detect MOST-1 transcripts by 
Northern blot analysis. It is then tempting to speculate the reason why MOST-1 
is present is such low amounts in tissues suggesting that if high amounts of 
MOST-1 maybe toxic to cells, there may be extensive regulation on its protein 
and mRNA level. These features are characteristic of many transiently 
expressed genes encoding small polypeptides involved in signaling or 
metabolic cascades that are being discovered at an accelerating pace.  
 
Chromosomal localization impact on MOST-1 function 
The chromosomal localization of MOST-1 to chromosome 8q24.2 is 
noteworthy as this region (and its vicinity) has been shown by many 
comparative genomic hybridization studies to be amplified mainly in ~50% 
breast and ~50-85% of prostate cancers, and also in ovarian, testicular, renal, 
bladder and colorectal tumors (Visakorpi et al., 1995; Forozan et al., 1997; 
Kuukasjarvi et al., 1997; Nupponen et al., 1998, 1999; De Angelis et al., 1999; 
Knuutila et al., 1999; Loveday et al., 1999). Another recent study using FISH 
in pathologic organ-confined prostate cancer showed a clinical significance of 
8q24 overrepresentation together with 8p22 loss results in poor prognosis in 
patients with high-grade, locally advance prostate cancer (Tsuchiya et al., 
2002). Although the localization of the c-myc proto-oncogene at 8q24.1 has 
been cited to account for many poorly differentiated prostate cancers, the entire 
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long arm of chromosome 8 is usually present at an increased copy number, 
suggesting that other genes may be involved (Visakorpi et al., 1995; Saramaki 
et al., 2001). For example, a gene that is differentially expressed during 
prostate cancer progression has been identified on chromosome 8q11 (Chang et 
al., 1999). Amplification of c-myc may not always correlate with 8q 
amplification in breast and prostate cancers (Nupponen et al. 1998, 1999). 
Other genes located at the 8q24.2 region are the PSGA gene mentioned above, 
a prostate-specific gene that apparently plays a role in prostate cancer 
progression (Reiter et al., 1998), and the brain adenylyl cyclase gene HBAC1 
(Stengel et al., 1992). This locus has also been implicated in various diseases 
such as partial trisomy 8q where patients suffer from psychomotor retardation 
(Stengel-Rutkowski et al., 1992), and hereditary spastic paraplegia in which the 
dominant HSP gene has been localized to 8q23-q24 (Hedera et al., 1999). 
Diseases associated with 8q for which the exact disease locus has yet to be 
discovered include autosomal recessive achromatopsia with defective 
photoreceptors (Milunsky et al., 1999), retinitis pigmentosa (Inglehearn et al., 
1999), and tibial hemimelia in Langer-Giedion syndrome (Stevens and Moore, 
1999). A recent study by Dekken et al showed that the gain of distal 8q 
discriminates between progressors and nonprogressors. These taken together 
support a new school of thought that amplification of genes in cancer 
commonly occurs in large amplicons such that several genes are amplified 
together. These genes are often involved in either similar pathways or systems. 
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The amplification of the chromosomal locus coinciding with that of 
MOST-1 in breast and prostate malignancies prompted the analysis of 
quantitative PCR experiments to determine MOST-1 RNA and DNA levels in 
frozen breast cancers and archival prostate tumors versus normal tissues. Two 
fifths of breast cancers exhibited MOST-1 overexpression, concurring with 
previous comparative genome hybridization studies that revealed amplification 
of 8q24.2 in these tumors. Compared with lower grade breast cancers, those of 
grade 3 showed higher T:N ratios of MOST-1 transcript levels of up to 13.5. 
Relative to normal prostate specimens, benign prostatic hyperplasia samples 
displayed an average 1.4-fold increase in MOST-1 DNA levels, while up to 
approximately 10-fold amplification was observed in prostatic cancers 
especially those of higher grades and Gleason scores.  In conclusion, 
aberrations of MOST-1 expression and copy number appear to be associated 
with substantial subsets of breast and prostate carcinomas, especially those of 
higher grade.   
 
MOST-1 Protein 
The next step would then proceed to polyclonal antibody production 
toward MOST-1 for protein characterization. Prior to antibody production, the 
putative ORF of MOST-1 was analyzed and several interesting predicted sites 
gave insights to protein function and localization. One of which is the N-
myristoylation site occurring at Glycine 2. N-myristoylation is a covalent 
protein modification that can promote the association of proteins with 
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membranes (De Jonge et al, 2000). Another site is the casein kinase II 
(otherwise known as protein kinase II) phosphorylation in which protein kinase 
II has been proposed to undergo rapid modulations in its association with 
nuclear matrix and nucleosomes in response to mitogenic signals and 
phosphorylation of proteins depending on the state of genomic activity. This 
association may influence the apoptotic activity in the cells (Ahmed et al. 
2000). The third site which is a protein kinase C phosphorylation site is also 
significant as protein kinase C has been shown to exert both inhibitory and 
stimulatory influences on apoptosis depending on the isoforms involved 
(Gutcher et al, 2003). Another interesting structure prediction was the extended 
sheet conformation predicted in almost half the protein amino acid content 
suggesting a high possibility for aggregation in solution. In addition, protein 
analysis suggests that MOST-1 is unstable in nature. These findings suggest 
that MOST-1 may be either associate with membranes or in vesicular structures 
or have a high propensity to aggregate or oligomerize. Protein oligomerization 
has been reported in studies with rhodopsin which is coincidentally a G-protein 
coupled receptor responsible for the capture of light as an initial step in 
phototransduction. SDS-PAGE analysis of this rhodopsin results in a ‘ladder’ 
of protein bands indication of oligomerization. This may explain the high 
molecular weight seen of MOST-1 in western analysis of cell lysates. Serine 91 
is predicted to be a site of O-glycosylation. Glycosylation was thought to be the 
factor contributing to the larger than expected molecular size. It has been 
reported that aberrant glycosylation has been implicated in the oncogenic 
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transformation and subsequently in the induction of invasion and metastasis , 
also protein glycosylation have been shown to contribute >50% by weight to 
the molecular weight of proteins (Fattoraossi et al, 2002; Litman et al, 2002; 
Carter et al, 2002; Hakomori 2002). MOST-1 ORF contains ~17% 
serine/threonine residues which are potential sites for O-linked glycosylation. 
Deglycosylation assay was done and shown that MOST-1 is unlikely to be 
glycosylated. 
 
Aggregation and implication of MOST-1 function 
Concurrent experiments to characterize the polyclonal antibody did 
however suggest the ability of MOST-1 to aggregate especially in cancer cell 
lines. Misfolded conformation has been reported in other studies with cancer 
cells. Protein conformation diseases (PCD) in which altered protein 
conformation has been sighted as a common feature which can result in loss of 
catalytic activity, structural functions and stability. This in turn will lead to 
accumulation of abnormal proteins which may results in protein aggregation. 
PCD can be divided into 2 groups, one in which aggregation of large masses of 
misfolded protein results in destruction of cells or the other where genetic 
errors results in misfolded conformation. The former include disorders such as 
Alzheimer’s disease and Parkinson’s diseases while the latter include cystic 
fibrosis, inherited emphysema and many types of cancer (Ishimaru, 2003). As 
high as 30% of all newly synthesized cellular proteins are defective ribosomal 
products, these are degraded by proteosomes shortly after their synthesis in 
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normal or unstressed cells. Thus there is no accumulation of protein aggregates 
despite their continued production. The cellular ‘quality control’ machinery 
suppresses formation of aggregates by ensuring the fidelity of transcription and 
translation, use of chaperones for correct protein folding and use of 
proteosomes for degrading improperly folded polypeptides. Because protein 
aggregates are more stable than the intermediate conformers, to degrade 
misfolded substrates effectively, the proteosomes must compete for the 
intermediates before they aggregate (Reviewed by Kopito, 2000). It is however 
not clear, whether aggregation of misfolded proteins is a primary cause or 
merely a consequence of conformations diseases but recent reports have 
indicated that aggregation of misfolded proteins can be a selective process 
dependent on peptide composition which in turn show specificity in their 
intracellular distribution and association with other proteins (Milewki et al, 
2002). Deaggregation has been shown to be dependent on size with efficiency 
decreasing as size of aggregates increase (Diamant et al, 2000). On the other 
hand, one of the recent studies with p53, a tumor suppressor involved in ~50% 
of human cancers showed that heat denaturation produces granular-shaped 
aggregates which are similar to those found in early aggregation stages of α-
synuclein and amyloid-β. The same study also illustrates that cells with wild-
type p53, a tumor suppressor, can also have inactive p53. This is achieved by 
aggregates “locking” away the available pool of functional protein thus 
allowing malignant cells to arise (Ishimaru et al, 2003). A study involving 
guanidinobenzoatase shows that aggregation can result in a higher molecular 
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weight entity accompanied with a change in catalytic activity (Poustis-Delpont 
et al, 1994). Protein aggregation appears to be a double-edged sword whereby 
on one hand, they could be a third line of defense against harmful misfolded 
proteins by depositing them in a biologically inert form. On the other, 
occurrence of large protein aggregates could trigger further cell damage and 
thereby aggravating the deleterious effects of stress situations (Zatloukal et al, 
2002). Proteosomes clearance of MOST-1 may have been inhibited due to a 
faster rate of aggregation to stable compounds. MOST-1 protein distribution in 
the cytoplasm lends further supports that MOST-1 aggregation appears to be a 
stable structure within cytoplasmic stippling. Punctate protein pattern has been 
implicated to be associated with proteins in membrane bound organelles. 
Examples are cystain C to the endosomes and lysosomes in the cytoplasm of 
neurons (Deng et al, 2001), NuMA in nucleus (Gobert et al, 2001), CHMP1 
subnuclear region (Stauffer et al, 2001), NABC1 to cytoplasm itself (Beardsley 
et al, 2003) and CHMP4b to perinuclear area (Katoh et al, 2003). Taken 
together, punctate appearance of proteins in cells occur when they are either 
overexpressed, misfolded or organelle/vesicle bound. Similarly, the appearance 
of MOST-1 when overexpressed or deregulated in cancer cells could be an 
indication that MOST-1 ‘aggregation’ might somehow be aiding in cell 
survival and in itself maybe be a mechanism to buy some time for the cell to 
recover and sustain itself. This phenomenon is reiterated in the cell 
synchronization experiments whereby overexpression of MOST-1 is seen as 
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large round vesicles formation compared to low expression of MOST-1 in 
cytoplasmic stippling. 
 
Interactors and their possible function with MOST-1  
Y2H screen results in several candidates which seem to echo our initial 
aim of isolation of a gene involved in cancer progression or cell cycle. The 
bulk of the interactors are found to be either amplified or overexpressed in 
cancers and involved in energy metabolism or cell cycle. As the name 
suggested, creatine kinase isoenzymes catalyze the synthesis of 
phosphocreatine by adding a phosphate to creatine turning it into the high-
energy molecule phosphocreatine. Phosphocreatine is burned as a quick source 
of energy and it’s subsequently used in the regeneration of ATP in cell types 
where the consumption of ATP is rapid or sudden. Although CK is 
predominantly found in muscle cells, it has also been proposed that different 
creatine kinase isoforms serves as an energy shuttle between mitochondria and 
cytoplasmic creatine kinase in discrete cellular sites of high ATP turnover 
(Shen et al, 2002, De Groof et al, 2002; Manos et al, 1993). This is supported 
in studies in which isoenzyme-specific cellular localization and subcellular 
compartmentation of CK has been shown to have a direct functional coupling 
of membrane bound CK to the Na+/K(+)-ATPase in cells such as electrocytes, 
retina photoreceptor cells, brain, kidney, salt glands, placenta, pancreas, 
thymus, thyroid, intestinal cells etc (Wallimann T et al, 1994). Again, cellular 
localization appear to be of importance to the type of function of CK 
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suggesting that interaction with MOST-1 at the correct localization may have 
some effect in energy metabolism. CK is generally found in the cytosol and 
mitochondria (Shen et al,2002). With MOST-1 predominantly found in 
membrane bound sections, it is likely that this interaction is physiologically 
relevant. Iron is needed for normal cell growth and proliferation but excessive 
iron caused to formation of free radicals. Ferritin acts as the soluble storage 
form of iron in tissue that occur in both intracellular and extracellular 
compartments (Parthasarathy N et al, 2002). Ferritin consists of various 
combinations of heavy and light chains which results in multiple isoforms 
(Moroz et al, 2002). High serum levels occur in liver disease, infection, 
inflammation, or malignancy (Tsuji et al, 2002).  A study which investigated 
the molecular basis for iron depletion in human hepatocellular carcinoma 
showed tissue ferritin light chain (T-FLC) to be reduced to undetectable levels 
with 2D gel electrophoreses, however analysis of mRNA of T-FLC exhibits 
mRNA levels almost the same as those in normal tissues. This suggests that 
translational or post-translational modification may be the cause of its 
suppression (Park KS et al, 2002). In addition, Ferritin has been shown to have 
immunoregulatory properties with effect to control iron overload which seem 
to impair the generation of cytotoxic T-cells (Walker et al, 2000). This may 
have implication in cancer progression in which cancer cells escape the host 
immune system recognition. Perhaps interaction of ferritin with MOST-1 might 
also ‘lock’ available ferritin pool which then results in iron overload and hence 
cancer progression. This might be an explanation to the higher expression of 
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MOST-1 in high grade breast and prostate cancer. Ferritin intracellular 
distribution occurs in discrete pools in the cytosol when not secreted 
(Parthasarthy et al,2002) , this subcellular distribution is seen also for MOST-1, 
again suggesting a possible physiological relevant interaction. Peripheral 
benzodiazepine receptor (PBR) appears to function to transport cholesterol 
across mitochondrial membrane (Chaki et al, 1999). It is a critical component 
of the mitochondrial permeability transition pore (MPTP) which is a 
multiprotein complex located between inner and outer mitochondrial 
membranes. MPTP has been shown to be involved in the initiation and 
regulation of apoptosis (Galiegue et al, 2003). Interestingly, PBR is a small 
evolutionary conserved protein which plays important regulation of apoptosis, 
cell proliferation, stimulation of steroidogenesis, immunomodulation, 
porphyrin transport, heme biosynthesis, anion transport and regulation of 
mitochondrial functions (Galiegue et al, 2003). This coincides with the 
genomic structure of MOST-1 and the hypothesis that there may be regulatory 
elements involved in MOST-1 expression. At the expression level, PBR 
overexpression has been seen in aggressive phenotype of breast, colorectal and 
prostate cancer (Papadopoulo V, 2003). Again this coincide with our findings 
that MOST-1 is overexpressed in high grade breast and prostate cancers. A 
recent PBR ligand study shows that ligands of PBR induce apoptosis and cell 
cycle arrest in esophageal cancer cells (Sutter et al, 2003). Another study 
suggests that binding of nanomolar concentration of PBR ligands protects cells 
against apoptosis (Strohmeier R et al, 2002). This contradictory role appears to 
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be present in MOST-1 overexpression and RNAi studies as well suggesting 
that the concentration and localization of MOST-1 might be important in 
determining its function. Another interactor of MOST-1 is SNC73 protein, a 
novel immunoglobulin protein which has been found to be down-regulated in 
colorectal cancer. The protein is one of the immunoglobulin heavy chain 
molecules with its constant region identical to that of IgA1 (Hu et al, 2003). 
This in addition to the interaction with immunoglobulin C (mu) and C (delta) 
heavy chain genes and other interactors above which are immunoregulators 
suggest MOST-1 to be closely associated with immune system and may 
function to evade immune surveillance of cancer cells. Interestingly, there is an 
interaction with an oncogene, v-FGR. This oncogene encodes a chimeric 
oncoprotein composed of feline sarcoma virus derived gag and cellular derived 
actin and c-Fgr sequences. v-FGR must be myristyolated and membrane bound 
to induce cellular transformation re-confirming that post-translation 
modification and subcellular localization is necessary for certain protein 
function (Baker et al, 1998). Interaction with this protein could have again 
explaining MOST-1 amplification in high grade breast and prostate cancers and 
suggest a role of MOST-1 in cellular transformation. Titin has been reported to 
control assemble and elasticity in chromosomes. Activated titin kinase 
phosphorylates telethonin which is a protein of cardiac and skeletal muscle. 
Telethonin has been identified as a sarcomeric Z-disk protein and has been 
shown to be involved in the reorganization of the cytoskeleton during 
myofibrillogenesis (Mayans et al, 1998). However since MOST-1 is not found 
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in these tissues under normal circumstances suggest that this interaction might 
be a non-existent in physiological conditions. A summary of the interactors 
functions are shown in Table 11.  
 







delta) heavy chain regions






Has  a role in  energy metabolism in cells with high and fluctuating energy requirements e.g. skeletal, cardiac, neural
tissues and spermatozoa.
B-CK is the isoform found in non-muscle cells and found to be overexpressed in solid tumors and cells lines such as
breast and prostate carcinoma.
Postulated to be the energy source for malignant cells.
Function to store and release Iron (II) in a controlled fashion but can act as a double-edged sword by encouraging
formation of cancer-causing free radicals.
High serum ferritin levels are associated with inflammation, liver disease,  anemia, thalassemia, malignant disease e.g.
leukemia, malignant lymphoma and breast cancer
It is also a risk factor for primary hepatocellular carcinoma.
Found in mitochondria and is a key factor in the flow of cholesterol in liver.
Appear to be involved in early apoptosis.
Involved in the differentiation of immunoglobulin for the formation of IgM and IgD.
Belongs to the RNA tumor  virus tyrosine-kinase oncogene family which causes C-terminal truncation and thus loss of
phosphorylatable tyrosine residues.
Encodes one Ig heavy chain with constant region identical to IgA1. Expression is lowered in colorectal cancerous tissue
compared to non-cancerous colorectal mucosa.
Sarcomeric Z-disk protein; involved in the reorganization of the cytoskeleton during myofibrillogenesis.
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MOST-1 Expression and Cell Cycle 
Interestingly, the novel prostate stem cell antigen (PSCA) prostate-
specific gene with homology to a G-protein-coupled receptor is also 
overexpressed in prostate cancers (Xu et al., 2000). PSCA is located in the 
same locus as MOST-1 8q24.2. This suggest a focus of prostate related genes 
located in this locus which when deregulated, increases the risk of prostate 
cancer development. Cell line profiling shows that MOST-1 was expressed in 
all the human cancer cell lines tested, but only in specific normal human adult 
tissues. Another significant finding was the detection of MOST-1 mRNA in 
human fetal lung but not in adult lung tissue, suggesting that MOST-1 
expression is dependent on tissue differentiation. This supports the implication 
of MOST-1 in the process of carcinogenesis. Its gene expression somehow 
becomes altered and since with efficient translation due to the ideal Kozak 
sequence and suggests that the MOST-1 protein may actually enable the better 
survival of cancer cells.  
However, there appears to be no correlation of MOST-1 to cell cycle. 
This observation is confirmed with cell synchronization experiments on breast 
normal and cancer cell lines synchronized with mimosine (Figure 15) but 
MOST-1 appears to accumulate in the cytoplasm during cell senescence, i.e. 
when majority of the cells are not undergoing cell division. In addition, cell 
synchronization experiments suggest a biological ‘timing’ of the expression of 
MOST-1 both in cancer and normal breast cells given the complete 
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disappearance of MOST-1 expression at certain times namely, 8-12h for MCF 
7 cells and 10-12h and 48h for normal mammary cells. 
Subsequently, overexpression and RNAi studies were done and assayed 
with cell proliferation assay and cell death assay to give an insight on the 
impact of MOST-1 expression. Overexpression seems to be difficult to achieve 
which once again lends support that there maybe additional regulatory 
mechanism which limit the amount of MOST-1 transcripts in the cells. While 
RNAi knock down shows a further increase in cell proliferation for prostate 
normal cells but not for carcinoma cell line, perhaps due to the existing levels 
of MOST-1 in carcinoma cell line being higher than in prostate normal cell 
lines. A point to note is the high level of proliferation present in DU145 even 
without treatment relative to the rest of the cell lines tested. Graph 3B shows an 
increase in DU145 cell death both when MOST-1 is overexpressed and knock 
down but more so when MOST-1 is overexpressed. Prostate normal cells show 
only increase in cell death when MOST-1 is knock down but not when 
overexpressed. A point to note is the high level of cell death in BHK cells 
relative to the rest of the cell lines tested. In conclusion, RNAi causes cell 
population to be two extremes, increase in cell proliferation and increase in cell 
death. For cancer prostate cell line, DU145, there is an increase in cell 
proliferation when MOST-1 is overexpressed and yet a corresponding increase 
in cell death suggesting again two population of cells which react differently to 
the levels of MOST-1 while RNAi causes increase in cell death. There is no 
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significant changes for the other cell lines tested due to the high standard 
deviation in the percentage of cells.  
 
Current Perspectives and Future Directions 
Any study with novel gene tends to be a difficult endeavor due to the 
unlimited possibilities of what the gene function might be. This study has 
characterize the genetic component of MOST-1 to correlate with high grade 
cancer biopsies of breast and prostate. Initial protein and functional study 
undertaken here succeeded in giving a ‘hint’ that the function of MOST-1 
protein might be to aid in cell survival especially in cancer cells. Perhaps more 
in depth study would give a better picture to where MOST-1 protein stands in 
cancer progression. Interactors ‘fished’ out by Y2H screen suggest that MOST-
1 might be involved in energy metabolism which is vital to cell survival, 
immune evasion which is vital for cancer cell proliferation and progression and 
cell cycle regulation. In a bid to conserve energy, cells may be required to go 
into G1 resting phase thus MOST-1 accumulation may act as a link to a sensor 
of the energy state of the cell and in turn affect cell cycle.  This hypothesis may 
explain the contradictory effects in which MOST-1 has in the functional 
analysis when it is either overexpressed or knock down. MOST-1 appears to 
have different functions in different cells at different expression levels at 
different subcellular localization making it a candidate choice when it comes to 
overexpression for cancer cell survival. In addition, since cancer is a 
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multifactor disease, environmental cofactors maybe needed for cell 
carcinogenesis to proceed following MOST-1 deregulation.  
With this study as a platform for the initial characterization of MOST-1 
gene and its potential protein function, we can envisage how different 
directions will the next phase of research embark to address the issues of 
MOST-1 with cancer progression, aggregation and evolutionary implication. 
Since it is found that MOST-1 is likely to be in the microsomal fraction and its 
interaction with a number of mitochondria and membrane bound proteins, 
further characterization of its subcellular localization can be done with specific 
organelle markers either by confocal microscopy or fractionated Western 
analysis. Investigation into the post-translation modifications predicted should 
be undertaken. Site directed mutagenesis to the N-myristoylation site can be 
done and observed to change in MOST-1 localization compared to wild-type.  
In vitro phosphorylation reaction could also be done to address the two other 
possible post-translation modifications. Taken together, this study have suggest 
that MOST-1 can serve as a differentiating tool of breast and prostate tumor 
progression, is probably evolutionary conserved and may be needed in small 
amount for cell survival but upon excess, protein aggregation takes place. 
Aggregation of MOST-1 may be protective in nature where by free MOST-1 is 
‘lock’ away in aggregates and non-functional. At the same time, cancer cells 
have the interesting ability to tolerate high expression of MOST-1 suggesting 
that there may be other mechanisms to tolerate the aggregates in exchange for 
better cell survival.  
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Future studies involving immunoprecipitation of the aggregated protein 
and its possible components would allow further insight and confirmation of its 
interactors and functions. Co-expression of MOST-1 and chaperones could also 
be done to address its propensity to aggregate or misfold upon over expression. 
Characterization of the aggregated component with γ-tubulin and ubiquitin for 
aggresome formation can also be undertaken. At the same time, co-localization 
of endogenous MOST-1 with its interactors at different cell stage and type 
would lend insight to its function based on its localization and interaction. 
Since MOST-1 gene is locate near HPV 18 integration site, future studies 
involving the analysis of cervical carcinoma biopsies would address MOST-1 
relevance in HPV-induced carcinogenesis. Figure 24 summarizes the 
characterization of MOST-1 in this study.  
In conclusion, with recent studies showing nonrandom HPV integration 
into sites which are linked to genetic aberrations in cancers (Feber et al, 2003) 
and the observation that amplification of 8q can be used to discriminate 
progressor and nonprogressors in prostate cancer (Dekken  et al,2003), the 
future identification of MOST-1 function and role in carcinogenesis would 
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Appendix 1: Mammalian cell tissue culture media 






NaCl was dissolved separately before adding to the already dissolved 3 
chemicals. pH was then adjusted to 7.4. 1X PBS was then prepared by diluting 
the stock to 10L and then filtered sterilized with 0.2µm bell filter (Whatman 
#6727-5002). 
 
1.2. Eagle’s modified essential medium 
With Earle’s BSS and 2mM L-glutamine 
NaHCO3 1.5g/L 
1M Hepes 2% 
Sodium pyruvate 1mM 
Nonessential amino acids 0.1mM 
Fetal bovine serum 10% 
 
1.3.Dulbecco’s modified eagle’s medium (Sigma #D7777) 
NaHCO3 3.7g/L 
1M Hepes 2% 




1.4.RPMI-1640 medium (Sigma #R4130) 
NaHCO3 1.5g/L 
Hepes 25mM 
Fetal bovine serum 10% 
 
1.5.Penicillin/Streptomycin (1000X) 
Penicillin G sodium BP (Glaxo) 5 x 106 U 






Appendix 2: Buffers and Reagents for Genome Work  
Template isolation 





2.2.SSE equilibrated phenol 
Phenol was melted at 55°C for 1 hour or until liquid. SSE pH 7.0 was added 
and stirred for 2 hours prior to phase separation O/N. pH of Phenol was 
monitored with successive change of SSE until pH of Phenol = 7.0. 
 








Nonidet P-40 0.65% 
 







Tris-HCl  10mM 
 
Northern Blot Analysis 
2.5 20XSSC, pH 7.0 
NaCl 3M 
Na Citrate 0.3M 
 









Appendix 3: Buffers and Reagents for Proteome Work  
Western Analysis 
3.1 10X Sample Buffer 
1M Tris, pH 6.8 625ul 
10% SDS 2ml 
2-β-mercaptoethanol 0.5ml 
Glycerol 1ml 
Bromophenol Blue 0.0025g 
ddH2O Top up to 10ml 
 




ddH2O Top up to 100ml 
Dilute 10x for each run. 
 
3.3 Acrylamide Monomer (30%) 
Acrylamide 30g 
N,N-Bisacrylamide 0.8g 
ddH2O Top up to 100ml 






3.4 Blocking Solution 
Bovine Serum Albumin 3% 
Gelatin 0.25% 
NaCl 150 mM 
Tris-HCl (pH 7.4) 15 mM 
 
3.5 TBST, pH 7.4 
NaCl 150 mM 
Tris-HCl (pH 7.4) 15 mM 
Tween-20 0.05%] 
 
3.6 Alkaline phosphatase buffer, pH9.5 
NaCl 2.922g 
MgCl2 0.508g 
1M Tris HCl, pH 7.5 50ml 
ddH2O 450ml 
 Adjust to pH 9.5 and add ddH2O to a final volume of 500ml 
 
3.7 CAPS TRANSFER BUFFER (1 liter) 
CAPS 1X 
Methanol 10% w/v 











 pH was adjusted to 11.0 with 5N NaOH before adding ddH2O to 1 litre. 
 
3.9 NBT (30mg/ml) 
NBT was dissolved in 1ml of 70% DMF. 
 
3.10 BCIP (15mg/ml) 
BCIP was dissolved in 1ml of 100% DMF. 
 
3.11 NBT/BCIP Color Development solution 
Just prior to use, mix 1ml of NBT and 1 ml of BCIP in 100ml of Tris Buffer 
 
3.12 Tris Buffer for Color Development (pH 9.5) 
0.1M Tris, 0.5mM MgCl2 dissolved in ddH2O. 
 
Protein extraction 
3.13 Lysis Buffer I 
Sodium Deoxycholate 1% 
Triton-X 100 1% 
Tris-HCL pH7. 0.1 M 




3.14 Lysis Buffer II 
Nonidet P-40 [NP 40] 0.02% 
NaCl 150 mM 
MgCl2 2 mM 
CaCl2 3 mM 
DTT 3 mM 
 
Indirect Immunofluorescence  
3.15 3% Paraformaldehyde (3%PFA) Fixative 
40ml of PBS was heated to 60°C before 3% of PFA (Sigma) was added and 
mixed for 30min. 10M NaOH was added until solution becomes clear and pH 
was adjusted to pH 6.1. Additional PBS was then added to make a total 
volume of 50ml. Solution was aliquot and stored at -20°C until use. Freeze-
thaw cycle was not permitted. 
 
3.16 Permeabilizing Agent 0.1% Triton X-100 
10% Triton X-100 (in ddH2O) 1ml 
PBS 99ml 
 
3.17 Blocking Solution 
0.1% FCS in PBS. 






Yeast two hybrid 
3.19 Yeast Peptone Dextrose (YPD) 
Yeast extract 1% 
Peptone 2% 
Dextrose 2% 
 18 g/L of agar was added when needed. 
3.20 Dropout media 
All reagents for synthetic dropout (SD) media/agar were purchased from Clontech 
and prepared according to recommended protocols.  
 
3.21. β-Galactosidase filter assay (Colony Lift) 






3.21.2. X-Gal Stock Solution 
5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal) was 




3.21.3. Z Buffer/X-Gal solution 




X-gal stock solution 1.67ml 
 
Cell synchronization studies 
3.22.  Mimosine Stock Solution 
L-Mimosine from Koa Hoale Seeds (Sigma, M0253) 25mg 
Minimal Essential Media (MEM) 12.6ml 
 
3.23. Propidium Iodide (PI) DNA Staining Solution 
0.1% (v/v) Triton X-100 (in PBS) 10ml 
DNase-free RNase A (Sigma; treated in 95°C for 5min) 2mg 



















Brain 3.863636 197.4474 0.019568 
Heart 48.51667 189.6081 0.255879 
Kidney 69.20635 221.4767 0.312477 
Liver 66.40952 216.6216 0.306569 
Lung 30.55 182.5426 0.167358 
Pancreas 74.03922 224.7609 0.329413 
Placenta 113.2449 206.9568 0.547191 
Skeletal 
muscle 27.39394 194.4567 0.140874 
Colon 129.8857 213.3025 0.608927 
Ovary 122.6579 215.2632 0.569804 
Peripheral 
blood 
leukocyte 14.975 182.7232 0.081955 
Prostate 14.78431 228.4171 0.064725 
Small intestine 29.64912 177.2917 0.167234 
Spleen 0.628788 173.3736 0.003627 
Testis 64.7 195.0083 0.331781 


















CaSki 191.6825 225.5429 1.176648 
HeLa 214.61 202.33 1.060693 
Hep3B 185.23 194.84 0.950677 
HepG2 208.18 192.74 1.080108 
HL60 228.03 241.1 0.94579 
Kato 162.57 213.45 0.76163 
Mahlavu 147.21 229.67 0.640963 
Molt-4 216.67 231.31 0.936708 
PP5 158 228.89 0.690288 
Raji 232.46 241.85 0.961174 
SiHa 216.28 240.68 0.898621 
T24 196.07 229.07 0.855939 
U937 232.33 145.72 1.594359 
MDA-MB-231 223.21 105.98 2.106152 
MCF7 230.49 204.42 1.127532 
DU145 218.77 192.77 1.134876 
PC3 211.67 176.83 1.197025 
Hs578t 224.92 196.47 1.144806 
Myoepithelial  213.96 185.85 1.151251 
MRC-5 230.18 170.15 1.352806 
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Appendix 5: Breast Biopsies Quantification  
Sample Number Histological Grade Ratio T/N 
1.  1 0.664111 
2.  1 0.483586 
3.  1 0.489579 
4.  2 0.933669 
5.  2 0.648018 
6.  2 1.179893 
7.  2 0.120742 
8.  2 1.152283 
9.  2 0.964672 
10.  2 1.379124 
11.  2 0.518576 
12.  2 0.959337 
13.  2 0.773453 
14.  2 1.451111 
15.  3 0.87505 
16.  3 0.35832 
17.  3 4.152415 
18.  3 5.890413 
19.  3 1.569398 
20.  3 1.171173 
21.  3 0.850314 
22.  3 1.220777 
23.  3 1.03262 
24.  3 1.444185 
25.  3 1.061707 
26.  3 1.459491 




Appendix 6: Prostate Biopsies Quantification  
Sample Type Average ∆CT value 2 -∆CT 
Normal -4.507 22.73747 
 -2.5055 5.678461 
 -4.203 18.41743 
 -0.695 1.618884 
 -1.512 2.852051 
 0.4905 0.711778 
 -0.3435 1.268831 
 -4.2695 19.28624 
 -2.6835 6.424125 
 -3.738 13.3429 
 4.1995 0.054428 
 -4.629 24.74388 
 -0.282 1.215879 
 1.14 0.45376 
 -0.7345 1.663821 
 -0.342 1.267513 
 -1.3495 2.548238 
 -1.4095 2.656451 
 1.6785 0.312407 
Hyperplasia -3.8995 14.92335 
 -2.3875 5.232499 
 1.1775 0.442117 
 -0.8785 1.838463 
 -0.133 1.096572 
 -0.719 1.646041 
 -0.137 1.099616 
 0.6635 0.631345 
 0.152 0.900002 
 -1.1925 2.285484 
 1.7475 0.297817 
 1.7995 0.287274 
 2.3425 0.197168 
 1.7705 0.293107 
 -0.849 1.801252 
 1.204 0.43407 
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 1.541 0.343647 
 0.6375 0.642826 
 -1.319 2.494931 
 -2.307 4.94853 
 -0.696 1.620007 
Low -1.389 2.618971 
(Gleason Score 3-5) -3.825 14.17228 
 -1.489 2.806943 
 -1.7375 3.334568 
 -3.139 8.809133 
Intermediate -3.1645 8.966221 
(Gleason Score 6-7) -3.967 15.63817 
 -4.0695 16.78965 
 -4.4065 21.20746 
 -2.998 7.988917 
 -2.936 7.652865 
 -2.588 6.012646 
 -4.053 16.59872 
 -4.359 20.52059 
 -4.6935 25.87523 
 -2.3945 5.257948 
 -0.2275 1.170804 
 -0.947 1.92786 
 -0.1735 1.127791 
High -1.949 3.861068 
(Gleason Score 8-9) -4.552 23.45787 
 -5.302 39.45127 
 -2.561 5.901166 
 -4.013 16.14483 
 0.8355 0.560389 
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Appendix 7: Biopsies information 
Clinicopathological data of invasive ductal breast cancer patients from the 
Singapore General Hospital involved in this study graded according to Bloom et 
al 1957. 
 
Patient age, yr Tumor Size, cm Histological Grade 
49 6 2 
46 2.5 2 
48 2.5 2 
55 3 3 
50 3 2 
41 2 3 
58 5 3 
55 4 3 
42 2.5 3 
43 3 3 
64 2.8 2 
61 5 2 
57 2 2 
45 6 3 
51 2.5 3 
62 3.5 2 
40 3.7 2 
77 3 1 
71 4 1 
52 1.8 2 
33 6.5 3 
39 4 3 
86 5 3 
49 3.4 2 
52 4.5 3 
60 1.75 2 




Clinicopathological data of prostate cancer biopsies from the National University 
Hospital involved in this study graded according to Gleason Score. 
 
Patient age, yr Race Histological Grade Gleason Score 
77 Indian Adenocarcinoma 5 
74 Chinese Adenocarcinoma 7 
60 Chinese Adenocarcinoma 7 
75 Chinese  Adenocarcinoma 5 
72 Chinese Adenocarcinoma 7 
65 Chinese Adenocarcinoma 8 
77 Indian Adenocarcinoma 5 
67 Malay Adenocarcinoma 9 
61 Chinese Adenocarcinoma 3 
64 Chinese Adenocarcinoma 9 
65 Chinese Adenocarcinoma 6 
70 Malay Adenocarcinoma 6 
Unknown Chinese Adenocarcinoma 6 
74 Chinese Adenocarcinoma 5 
80 Chinese Adenocarcinoma 9 
74 Malay Adenocarcinoma 7 
63 Eurasia Adenocarcinoma 6 
84 Chinese Adenocarcinoma 7 
66 Chinese Adenocarcinoma 7 
84 Chinese Adenocarcinoma 7 
81 Eurasia Adenocarcinoma 7 
72 Malay Adenocarcinoma 8 
63 Eurasia Adenocarcinoma 7 
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